Cyproheptadine derivatives

Abstract

The present disclosure relates to cyproheptadine derivatives of Formula (I) or a pharmaceutically acceptable salt, solvate, or isomer thereof: Formula (I). Also provided are applications thereof for treating cancers.

Description

ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION CYPROHEPTADINE DERIVATIVES FIELD OF THE INVENTION The present disclosure relates to the field of pharmaceuticals, and more specifically, to cyproheptadine derivatives and the applications thereof for treating cancers. BACKGROUND Malignant tumors, or cancers, have long been one of the leading causes of death worldwide. Due to the many complex and unresolved causes of cancer, continuing with existing treatment methods or medications without seeking innovation may be insufficient to address potential issues faced in subsequent treatments. Therefore, the development of novel and effective treatment methods or drugs for cancer has always been the goal of many scientists. SUMMARY The present disclosure is directed to cyproheptadine derivatives, to compositions comprising thereof, and to methods of using thereof in a treatment of cancer or tumor. More particularly, the present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate or isomer thereof:wherein R1is H, halogen, or unsubstituted or substituted straight-chain alkyl or unsubstituted or substituted alkoxyl having 1 to 6 carbon atoms;ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION L is -C-C- or -C=C- X is C or N; Y is C, C(=O), S(=O)-O, or O-S(=O); Z is NHOH or a C2-C12ester; and n is an integer from 2 to 11. The present discourse further provides pharmaceutical compositions comprising one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s), hydrate or isomer thereof, and relevant pharmaceutical uses. The present discourse also provides a method for treating a cancer, comprising administering an effective amount of one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof to a subject. BRIEF DESCRIPTION OF DRAWINGS FIGs.1A and 1B) show the variation in tumor sizes / weights of mice no.1-5, orally administered with water, with treatment days. FIGs.2A and 2B show the variation in tumor sizes / weights of mice no.6-10, orally administered with a pharmaceutically acceptable salt of the compound of Formula (I), with treatment days. FIGs.3A and 3B shows the variation in tumor sizes / weights of mice no.11-15, injected with a pharmaceutically acceptable salt of the compound of Formula (I), with treatment days. Description The present disclosure is described in connection with several embodiments. However, it should be appreciated that the disclosure is not limited to the disclosed embodiments. It is understood that, given the description of the embodiments of the disclosure herein, various modifications can be made by a person skilled in the art. Such modifications are encompassed by the claims below. Definitions and TermsATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION Terms not specifically defined herein should be understood according to the meanings that would be given to them by one of skill in the art in light of the disclosure and the context. As used in the specification, however, unless specified to the contrary, the following terms have the meaning indicated according to the following conventions. The terms "a" and "an" as used herein refer to one or more. The terms "disease" and "disorder" as used herein can be used interchangeably. The terms "treatment" and "treating" as used herein embrace both preventative, i.e. prophylactic, or therapeutic, i.e. curative and / or palliative, treatment. Thus, the terms "treatment" and "treating" comprise therapeutic treatment of patients having already developed said disease or disorder, in particular in manifest form. Therapeutic treatment may be symptomatic treatment in order to relieve the symptoms of the specific indication or causal treatment in order to reverse or partially reverse the disease or disorder of the indication or to stop or slow down progression of the disease. Thus, the compounds, compositions and methods of the present disclosure may be used for instance as therapeutic treatment over a period of time as well as for chronic therapy. In addition, the terms "treatment" and "treating" comprise prophylactic treatment, i.e. a treatment of patients at risk to develop a disease or disorder mentioned hereinbefore, thus reducing said risk. The term "therapeutically effective amount" as used herein means an amount of a compound of the present disclosure that (i) treats or prevents the particular disease or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease or disorder described herein. The term "substituted" as used herein means that any one or more hydrogens on the designated atom, radical or moiety is replaced with a selection from the indicated group, provided that the atom's normal valence is not exceeded, and that the substitution results in an acceptably stable compound. The term "pharmaceutically acceptable" as used herein is employed herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of medical judgment, suitable for use in contact with the tissues of human beings and animalsATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit / risk ratio. As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (in this disclosure, a compound of Formula (I) or a salt or physiologically functional derivative thereof) and a solvent. Such solvents for the purpose of the disclosure may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, methanol, ethanol and acetic acid. For example, the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include, without limitation, water, ethanol and acetic acid. In some embodiments, the solvent used is water (i.e., the solvate is a hydrate). As used herein, the term "alkyl" may refer to saturated, straight or branched-chain hydrocarbon radicals containing, in certain embodiments, between one and six carbon atoms. For example, C1-C3alkyl includes methyl, ethyl, n-propyl, and isopropyl. Examples of C1-C6alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert- butyl, neopentyl, and n-hexyl radicals. In addition, the term "alkyl" as used herein also encompasses alkyl groups where one or more hydrogen atoms are replaced by atoms other than hydrogen. For instance, a hydrogen atom can be replaced by a halogen. More specifically, the hydrogen atom can be replaced by fluorine (F), chlorine (Cl), or bromine (Br). These alkyl groups are referred to as "haloalkyl" groups. Examples of such haloalkyl groups include, but are not limited to, fluoroalkyl, chloroalkyl, and bromoalkyl groups. As used herein, the term "alkoxy" may refer to an -O-alkyl radical. For example, C1- C3alkoxy includes methoxy, ethoxy, n-propoxy, and isopropoxy. Examples of C1-C6alkyl radicals include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, tert- butoxy, neopentoxy, and n-hexoxy radicals. As used herein, the term "halogen" may refer to an atom selected from fluorine, chlorine, bromine and iodine. As used herein, the term "ester" may refer to an organic compound made by replacing the hydrogen of an acid by an alkyl or other organic group. In other words, it is a radical derived from an acid (organic or inorganic) in which at least one -OH (hydroxyl) group is replaced by an -O-alkyl (alkoxy) group. For example, a C1-C3ester includes methylester, ethylester, n-propylester, and isopropylester. Examples of C1-C6ester radicals include, butATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION are not limited to, methylester, ethylester, propylester, isopropylester, n-butylester, tert- butylester, neopentylester, and n-hexylester radicals. As used herein, the term "pharmaceutically acceptable salt" may refer to those salts of the compounds formed by the process of the present application which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). The salts can be prepared in situ during the final isolation and purification of the compounds of the application, or separately by reacting the free base or acid function with a suitable acid or base. These salts may be formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and organic acids such as acetic acid, propionic acid. In some embodiments, these salts may be formed with alkali metals, alkaline earth metals, amino acids, or basic compounds containing amino groups; or formed with inorganic salts or organic acids. Compounds The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or isomer thereof as described herein. The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein one or more hydrogen atoms in R1are optionally replaced by F. The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1is H or Cl; L is -C-C- or -C=C-; X is C or N; Y is C or C(=O); Z is NHOH; and n is an integer from 2 to 11. The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C-C-, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C-C-, X is C, and the other parameters have theATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C=C-, X is C, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C-C-, X is N, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C=C-, X is N, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C-C-, Y is C, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C=C-, Y is C, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C-C-, Y is C(=O), and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C=C-, Y is C(=O), and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C-C-, Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C=C-, Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein X and Y denote C, and the other parameters have the meaning given in the radical list of Formula (I).ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein X is C, Y is C(=O), and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein X is N, Y is C, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein X is N, Y is C(=O), and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein X is C, Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein X is N, Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Y is C, Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Y is C(=O), Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C-C-, X and Y denote C, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is C=C-, X and Y denote C, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C-C-, X is C, Y is C(=O), and the other parameters haveATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is C=C-, X is C, Y is C(=O), and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C-C-, X is N, Y is C, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C=C-, X is N, Y is C, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C-C-, X is N, Y is C(=O), and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C=C-, X is N, Y is C(=O), and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C-C-, Y is C, Z is NHOH and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C=C-, Y is C, Z is NHOH and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C-C-, Y is C(=O), Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C=C-, Y is C(=O), Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein X and Y denote C, Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I).ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein X is N, Y is C, Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein X is C, Y is C(=O), Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein X is N, Y is C(=O), Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C-C-, X and Y denote C, Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C=C-, X and Y denote C, Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C-C-, X is N, Y is C, Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C=C-, X is N, Y is C, Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C-C-, X is C, Y is C(=O), Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C=C-, X is C, Y is C(=O), Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C-C-, X is N, Y is C(=O), Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). The present disclosureATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L is -C=C-, X is N, Y is C(=O), Z is NHOH, and the other parameters have the meaning given in the radical list of Formula (I). In some embodiments, the compound of Formula (I) may be selected from the group of the compounds of Formulae (Ia) and (Ib):a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, anda pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, wherein X is C or N; Y is C, C(=O), S(=O)-O, or O-S(=O), for example, is C or C(=O); Z is NHOH or a C2-C12ester, for example, is NHOH, or straight-chain or branched alkyl having 2 to 12 C atoms, in which, in addition, one or two non- adjacent CH2groups are replaced by -O-C(=O)- or -C(=O)-O- in such a wayATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION that O atoms are not linked directly to one another, for example, is NHOH; and n is an integer from 2 to 11, for example, is 2 to 9, for example, is 2 to 8. In some embodiments, the compound of Formula (I) may be selected from the group of the compounds of Formulae (Ia) and (Ib), wherein X is C or N; Y is C or C(=O); Z is NHOH; and n is an integer from 2 to 11. In some embodiments, the compound of Formula (I) may be selected from the group of the compounds of Formulae (Ia) and (Ib), wherein X and Y denote C, and the other parameters have the meaning given in the radical list of Formulae (Ia) and (Ib). In some embodiments, the compound of Formula (I) may be selected from the group of the compounds of Formulae (Ia) and (Ib), wherein X is C, Y is C(=O), and the other parameters have the meaning given in the radical list of Formulae (Ia) and (Ib). In some embodiments, the compound of Formula (I) may be selected from the group of the compounds of Formulae (Ia) and (Ib), wherein X is N, Y is C, and the other parameters have the meaning given in the radical list of Formulae (Ia) and (Ib). In some embodiments, the compound of Formula (I) may be selected from the group of the compounds of Formulae (Ia) and (Ib), wherein X is N, Y is C(=O), and the other parameters have the meaning given in the radical list of Formulae (Ia) and (Ib). In some embodiments, the compound of Formula (I) may be selected from the group of the compounds of Formulae (Ia) and (Ib), wherein X is C, Z is NHOH, and the other parameters have the meaning given in the radical list of Formulae (Ia) and (Ib). In some embodiments, the compound of Formula (I) may be selected from the group of the compounds of Formulae (Ia) and (Ib), wherein X is N, Z is NHOH, and the other parameters have the meaning given in the radical list of Formulae (Ia) and (Ib). In some embodiments, the compound of Formula (I) may be selected from the group of the compounds of Formulae (Ia) and (Ib), wherein Y is C, Z is NHOH, and the other parameters have the meaning given in the radical list of Formulae (Ia) and (Ib).ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION In some embodiments, the compound of Formula (I) may be selected from the group of the compounds of Formulae (Ia) and (Ib), wherein Y is C(=O), Z is NHOH, and the other parameters have the meaning given in the radical list of Formulae (Ia) and (Ib). In some embodiments, the compound of Formula (I) may be selected from the group of the compounds of Formulae (Ia) and (Ib), wherein X and Y denote C, Z is NHOH, and the other parameters have the meaning given in the radical list of Formulae (Ia) and (Ib). In some embodiments, the compound of Formula (I) may be selected from the group of the compounds of Formulae (Ia) and (Ib), wherein X is N, Y is C, Z is NHOH, and the other parameters have the meaning given in the radical list of Formulae (Ia) and (Ib). In some embodiments, the compound of Formula (I) may be selected from the group of the compounds of Formulae (Ia) and (Ib), wherein X is C, Y is C(=O), Z is NHOH, and the other parameters have the meaning given in the radical list of Formulae (Ia) and (Ib). In some embodiments, the compound of Formula (I) may be selected from the group of the compounds of Formulae (Ia) and (Ib), wherein X is N, Y is C(=O), Z is NHOH, and the other parameters have the meaning given in the radical list of Formulae (Ia) and (Ib). In some embodiments, the compound of Formula (Ia) may be selected from the group of the compounds of Formulae (Ia.1) and (Ia.2): (Ia.1),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, andATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATIONa pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, wherein Y is C, C(=O), S(=O)-O, or O-S(=O), for example, is C or C(=O); Z is NHOH or a C2-C12ester, for example, is NHOH, or straight-chain or branched alkyl having 2 to 12 C atoms, in which, in addition, one or two non- adjacent CH2groups are replaced by -O-C(=O)- or -C(=O)-O- in such a way that O atoms are not linked directly to one another, for example, is NHOH; and n is an integer from 2 to 11, for example, is 2 to 9, such as, is 2 to 8. In some embodiments, the compound of Formula (Ia) may be selected from the group of the compounds of Formulae (Ia.1) and (Ia.2), wherein Y is C or C(=O); Z is NHOH; and n is an integer from 2 to 11. In some embodiments, the compound of Formula (Ia) may be selected from the group of the compounds of Formulae (Ia.1) and (Ia.2), wherein Y is C, Z is NHOH, and the other parameters have the meaning given in the radical list of Formulae (Ia.1) and (Ia.2). In some embodiments, the compound of Formula (Ia) may be selected from the group of the compounds of Formulae (Ia.1) and (Ia.2), wherein Y is C(=O), Z is NHOH, and the other parameters have the meaning given in the radical list of Formulae (Ia.1) and (Ia.2). In some embodiments, the compound of Formula (Ib) may be selected from the group of the compounds of Formulae (Ib.1) and (Ib.2):ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION (Ib.1),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, and (Ib.2),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, wherein Y is C, C(=O), S(=O)-O, or O-S(=O), for example, is C or C(=O); Z is NHOH or a C2-C12ester, for example, is NHOH, or straight-chain or branched alkyl having 2 to 12 C atoms, in which, in addition, one or two non- adjacent CH2groups are replaced by -O-C(=O)- or -C(=O)-O- in such a way that O atoms are not linked directly to one another, for example, is NHOH; and n is an integer from 2 to 11, for example, is 2 to 9, such as, is 2 to 8. In some embodiments, the compound of Formula (Ib) may be selected from the group of the compounds of Formulae (Ib.1) and (Ib.2), wherein Y is C or C(=O); Z is NHOH; and n is an integer from 2 to 11.ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION In some embodiments, the compound of Formula (Ib) may be selected from the group of the compounds of Formulae (Ib.1) and (Ib.2), wherein Y is C, Z is NHOH, and the other parameters have the meaning given in the radical list of Formulae (Ia.1) and (Ia.2). In some embodiments, the compound of Formula (Ib) may be selected from the group of the compounds of Formulae (Ib.1) and (Ib.2), wherein Y is C(=O), Z is NHOH, and the other parameters have the meaning given in the radical list of Formulae (Ia.1) and (Ia.2). In some embodiments, the compound of Formula (Ia.1) may be selected from the group of the compounds of Formulae (Ia.1.1) and (Ia.1.2):a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, and (Ia.1.2),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, wherein Z is NHOH or a C2-C12ester, for example, is NHOH, or straight-chain or branched alkyl having 2 to 12 C atoms, in which, in addition, one or two non-ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION adjacent CH2groups are replaced by -O-C(=O)- or -C(=O)-O- in such a way that O atoms are not linked directly to one another, for example, is NHOH; and n is an integer from 2 to 11, for example, is 2 to 9, such as, is 2 to 8. In some embodiments, the compound of Formula (Ia.2) may be selected from the group of the compounds of Formulae (Ia.2.1) and (Ia.2.2): (Ia.2.1),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, and (Ia.2.2),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, wherein Z is NHOH or a C2-C12 ester, for example, is NHOH, or straight-chain or branched alkyl having 2 to 12 C atoms, in which, in addition, one or two non- adjacent CH2groups are replaced by -O-C(=O)- or -C(=O)-O- in such a wayATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION that O atoms are not linked directly to one another, for example, is NHOH; and n is an integer from 2 to 11, for example, is 2 to 9, such as, is 2 to 8. In some embodiments, the compound of Formula (Ib.1) may be selected from the group of the compounds of Formulae (Ib.1.1) and (Ib.1.2): (Ib.1.1),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, and (Ib.1.2),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, wherein Z is NHOH or a C2-C12ester, for example, is NHOH, or straight-chain or branched alkyl having 2 to 12 C atoms, in which, in addition, one or two non- adjacent CH2groups are replaced by -O-C(=O)- or -C(=O)-O- in such a wayATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION that O atoms are not linked directly to one another, for example, is NHOH; and n is an integer from 2 to 11, for example, is 2 to 9, such as, is 2 to 8. In some embodiments, the compound of Formula (Ib.2) may be selected from the group of the compounds of Formulae (Ib.2.1) and (Ib.2.2): (Ib.2.1),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, and (Ib.2.2),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, wherein Z is NHOH or a C2-C12ester, for example, is NHOH, or straight-chain or branched alkyl having 2 to 12 C atoms, in which, in addition, one or two non- adjacent CH2groups are replaced by -O-C(=O)- or -C(=O)-O- in such a wayATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION that O atoms are not linked directly to one another, for example, is NHOH; and n is an integer from 2 to 11, for example, is 2 to 9, such as, is 2 to 8. In some embodiments, the compound of Formula (Ia.1) may be selected from the group of the compounds of Formulae (Ia.1.1') and (Ia.1.2'):a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, anda pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, wherein n is an integer from 2 to 11, for example, is 2 to 9, such as, is 2 to 8. In some embodiments, the compound of Formula (Ia.2) may be selected from the group of the compounds of Formulae (Ia.2.1') and (Ia.2.2'):ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION (Ia.2.1'),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, and (Ia.2.2'),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, wherein n is an integer from 2 to 11, for example, is 2 to 9, such as, is 2 to 8. In some embodiments, the compound of Formula (Ib.1) may be selected from the group of the compounds of Formulae (Ib.1.1') and (Ib.1.2'):a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, andATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATIONa pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, wherein n is an integer from 2 to 11, for example is 2 to 9, such as, is 2 to 8. In some embodiments, the compound of Formula (Ib.2) may be selected from the group of the compounds of Formulae (Ib.2.1') and (Ib.2.2'):a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, anda pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof,ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION wherein n is an integer from 2 to 11, for example, is 2 to 9, such as, is 2 to 8. In some embodiments, the parameters of the compound of Formula (I) may have the meaning indicated in Table 1. Table 1 No. R1L X Y Z nATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION No. R1L X Y Z nThe present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein the parameters may have the meaning indicated in Table 1, Rows 1-8. The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein the parameters may have the meaning indicated in Table 1, Rows 9-16. The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein the parameters may have the meaning indicated in Table 1, Rows 17-24. The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein the parameters may have the meaning indicated in Table 1, Rows 25-32.ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein the parameters may have the meaning indicated in Table 1, Rows 33-40. The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein the parameters may have the meaning indicated in Table 1, Rows 41-48. The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein the parameters may have the meaning indicated in Table 1, Rows 49-56. The present disclosure may provide a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein the parameters may have the meaning indicated in Table 1, Rows 57-64. Additionally, salts, hydrates, and solvates of the present compounds also are included in the present disclosure and may be used in the methods disclosed herein. The compound of Formula (I) described herein may exist in various forms including, but not limited to, free base, salts, isomers, hydrates, solvates, and prodrugs. All forms described therebefore are considered to be within the scope of the present disclosure. The compound of Formula (I), its salts, isomers, hydrates, solvates, or prodrugs thereof, may be administered to a patient in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. Regardless of the form, the compound of Formula (I) retains its therapeutic properties and is effective in treating diseases or disorders associated with the proliferation of a cell. The compounds of the present disclosure can be prepared using methods known to those skilled in the art in view of this disclosure. The preparation of the embodiment compounds of the present disclosure is illustrated in the examples. In view of the present disclosure, it should be understood that the compound of Formula (I) can be prepared using the methods and procedures described herein, particularly those illustrated in the working examples provided in this specification. These methods and procedures can be generally modified within the extent of general knowledge in this field without departing from the scope of the disclosure. It is within the purview of those skilled in the art to make such modifications while maintaining the same function or result of the compound of Formula (I).ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION Therefore, all such modifications and variations are intended to be included within the scope of this disclosure. Pharmaceutical Compositions and Administration The present disclosure further provides a pharmaceutical composition comprising the one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In the pharmaceutical composition, the one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof may be present in a therapeutically effective amount. The pharmaceutically acceptable carrier may be a pharmaceutically acceptable excipient. The pharmaceutical compositions described herein are, e.g., formulated into pharmaceutical compositions for administration to human subjects in a biologically compatible form suitable for administration in vivo. The "pharmaceutically acceptable carrier" may refer to a non-toxic, inert substance that does not react with the the one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof and is safe for administration to a patient. Examples of such carriers include but are not limited to pharmaceutically acceptable excipients, diluents and auxiliaries. Pharmaceutically acceptable carriers and diluents are familiar to those skilled in the art. For compositions Formulated as liquid solutions, acceptable carriers and / or diluents include saline and sterile water, and may optionally include antioxidants, buffers, bacteriostats and other common additives. The compositions can also be formulated as pills, capsules, granules, or tablets which contain, in addition to a compound of the disclosure, diluents, dispersing and surface-active agents, binders, and lubricants. One skilled in this art may further formulate the compound(s) of the disclosure in an appropriate manner, and in accordance with accepted practices, such as those disclosed in Remington's Pharmaceutical Sciences, Gennaro, Ed., Mack Publishing Co., Easton, Pa.1990. The form of the pharmaceutical composition could be, for example, a tablet, a capsule, a solution, or a suspension. The composition could be designed for various routes of administration, including but not limited to oral, intravenous, intramuscular, or subcutaneous routes. The specific form and route of administration would depend on factors such as the specific disease or disorder being treated and the patient's disease or disorder.ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION As used herein, "therapeutically effective amount" may refer to the amount of the one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof that is sufficient to achieve the desired therapeutic effect, such as inhibiting cell proliferation in the case of cancer treatment. For example, in some embodiments, the specific amount would depend on factors such as the specific disease or disorder being treated, the patient's disease or disorder, and the patient's weight. The therapeutically effective amount may be determined by a physician or other healthcare professional. For oral administration, the compound(s) or pharmaceutical composition(s) of the present disclosure may be formulated in forms including, but not limited to, powders, granules, pills, tablets, lozenges, chews, gels, and capsules, as well as liquids, syrups, suspensions, elixirs, and emulsions. These compositions may also include antioxidants, flavorings, preservatives, suspending, thickening, and emulsifying agents, colorants, flavoring agents, and other pharmaceutically acceptable additives. Formulations for oral administration may be formulated to be immediate release or modified release, wherein modified release includes delayed, sustained, pulsed, controlled, targeted, and programmed release. For parenteral administration, the compound(s) or pharmaceutical composition(s) of the present disclosure may be administered directly into the blood stream, into muscle, or into an internal organ via an intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, or other injection or infusion. Parenteral formulations may be prepared in aqueous injection solutions which may contain, in addition to one or more compound of the present disclosure, buffers, antioxidants, bacteriostats, salts, carbohydrates, and other additives commonly employed in such solutions. Parenteral administrations may be immediate release or modified release (such as an injected or implanted depot, e.g., where the active agent is released over a designated time period to permit less frequent injections). The compound(s) or pharmaceutical composition(s) of the present disclosure may also be administered topically, (intra)dermally, or transdermally to the skin or mucosa. Typical formulations may include gels, hydrogels, lotions, solutions, creams, ointments, dressings, foams, skin patches, wafers, implants and microemulsions. The compound(s) or pharmaceutical composition(s) of the present disclosure may also be administered via inhalation or intranasal administration, such as with a dry powder, an aerosol spray or as drops. Additional routes of administration for compounds or pharmaceutical compositions ofATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION the present disclosure include intravaginal and rectal (by means, for example, of a suppository, pessary or enema), ocular, and aural. The pharmaceutical composition(s) of the present disclosure may also include one or more other ingredient(s), such as stabilizers, preservatives, or flavoring agents, as would be known to those skilled in the art. The pharmaceutical composition(s) of the present disclosure may be prepared using methods known in the art, such as by mixing one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof with the carrier and any other ingredients, and then formulating the mixture into the desired form. The compound(s) or pharmaceutical composition(s) of the present disclosure may be administered to a patient in need thereof, such as a patient who has been diagnosed with one of the types of cancer disclosed herein, such as, liver cancer, oral cancer, ovarian cancer, bladder cancer, lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, and / or gastric cancer. The composition may be administered in a single dose or in multiple doses over a period of time, as determined by a physician or other healthcare professional. The compound(s) or pharmaceutical composition(s) of the present disclosure may be used alone or in combination with other treatments, such as surgery, radiation therapy, or other drugs. The one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof in the pharmaceutical composition(s) of the present disclosure may be used to inhibit cell proliferation, thereby treating the disease or disorder. The compound(s) or pharmaceutical composition(s) of the present disclosure may be used in combination with one or more second therapeutic agent(s). In some embodiments, for example, but without limitation, the second therapeutic agents are agents suitable for the treatment and / or prevention of the disease and disorders described in the present disclosure. In some embodiments, for example, in cancer treatment, a second therapeutic agent may include a mitotic inhibitor (such as a taxane (e.g., paclitaxel or docetaxel), vinca alkaloid (for example, but without limitation, vinblastine, vincristine, vindesine or vinorelbine) or vepesid; an anthracycline antibiotic (for example, but without limitation, doxorubicin, daunorubicin, daunorubicin, epirubicin, idarubicin, valrubicin or mitoxantrone); a nucleoside analog (for example, but without limitation, gemcitabine); an EGFR inhibitor (for example, but without limitation, gefitinib or erlotinib); a folate antimetabolite (for example, but without limitation, trimethoprim, pyrimethamine or pemetrexed); cisplatin or carboplatin. Examples of a secondATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION therapeutic agent include but are not limited to tamoxifen, taxol, vinblastine, etoposide (VP-16), adriamycin, 5-fluorouracil (5-FU), camptothecin, actinomycin-D, mitomycin C, combretastatin(s), more particularly docetaxel (taxotere), cisplatin (CDDP), cyclophosphamide, doxorubicin, methotrexate, paclitaxel and vincristine, and derivatives and prodrugs thereof. The second therapeutic agent may be an anti-cancer drug, such as immune checkpoint inhibitors (including but not limited to: toripalimab, pembrolizumab, nivolumab, or atezolizumab), IAP antagonists (xevinapant), tumor infiltrating lymphocytes, leukocyte interleukin, farnesyltransferase inhibitors, and the like. These agents may provide synergistic effects when used in combination with one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof. In some embodiments, additional useful second therapeutic agents may include compounds that interfere with DNA replication, mitosis, chromosomal segregation and / or tubulin activity. Such compounds may include adriamycin, also known as doxorubicin, etoposide, verapamil, podophyllotoxin(s), combretastatin(s) and the like. In some embodiments, therapeutic agents that disrupt the synthesis and fidelity of polynucleotide precursors may also be used. Examples of useful therapeutic agents are, without limitation, agents that have undergone extensive testing and are readily available. In some embodiments, agents such as 5-fluorouracil (5-FU) are, for example, preferentially used by neoplastic tissue, making this agent particularly useful for targeting neoplastic cells. Pharmaceutical Uses In some embodiments, one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof, or a pharmaceutical composition comprising one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof may be used in treating a disease or disorder. The present disclosure further provides a method for treating a disease or disorder. The method for treating a disease or disorder may comprise administering to a subject a therapeutically effective amount of one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof, or a pharmaceutical composition comprising one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof. The present disclosure further provides a use of one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof, or a pharmaceutical composition comprising one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof, for treating a disease or disorder. The present disclosure further provides a use of theATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION compound(s) of Formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof for the manufacture of a medicament for treating a disease or disorder, comprising administering to a subject a therapeutically effective amount of one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof, or a pharmaceutical composition comprising one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof. In some embodiments, one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof, or a pharmaceutical composition comprising one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof may be used in inhibiting the proliferation of a cell. The present disclosure further provides a method of inhibiting the proliferation of a cell. The method of inhibiting the proliferation of a cell may comprise exposing a cell with an effective amount of one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof, , or a pharmaceutical composition comprising one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof. The present disclosure further provides a use of the compound(s) of Formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof for inhibiting the proliferation of a cell. The inhibition of the proliferation of a cell may be performed in vivo. The inhibition of the proliferation of a cell may be performed in vitro. The inhibition of the proliferation of a cell may be performed ex vivo. In some embodiments, the disease or disorder may be associated with the proliferation of a cell in a subject. The disease or disorder may be a type of cancer. The cancer may be selected from the group consisting of liver cancer, oral cancer, ovarian cancer, bladder cancer, lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, and gastric cancer. The cancer may be selected from the group consisting of liver cancer, oral cancer, ovarian cancer, bladder cancer, breast cancer, colorectal cancer, and gastric cancer. The cancer may be selected from the group consisting of liver cancer, oral cancer, ovarian cancer, breast cancer, colorectal cancer, and gastric cancer. The cancer may be selected from the group consisting of liver cancer, oral cancer, and breast cancer. In some embodiments, the cell may be a cancer cell. In some embodiments, the cell may be a cancer cell associated with the cancers described herein. In some embodiments, theATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION cell may be selected from the group consisting of HepG2, OML-1, MOC2, A2780, Kuramochi, UMUC3, J82, BFTC 905, A549, H460, MCF-7, MDA-MB231, PC3, 22RV1, BxPC3, SW1990, HT-29, DLD-1, AGS, and MKN45. In some embodiments, the cell may be selected from the group consisting of HepG2, OML-1, A2780, Kuramochi, BFTC 905, MCF- 7, MDA-MB231, HT-29, DLD-1, AGS, and MKN45. In some embodiments, he cell may be selected from the group consisting of HepG2, A2780, MDA-MB231, HT-29, and MKN45 cell lines. In some embodiments, the cell may be selected from the group consisting of HepG2 and MKN45 cell lines. Kits The present disclosure also encompasses kits including (a) a pharmaceutical composition comprising one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof, and (b) a package insert with instructions to perform any of the methods described herein. In some embodiments, the kit includes (a) a pharmaceutical composition comprising one or more compound(s) of Formula (I) or a pharmaceutically acceptable salt(s) thereof (b) an additional therapeutic agent (e.g., an anti-cancer agent), and (c) a package insert with instructions to perform any of the methods described herein. Non-Limiting List of Exemplary Embodiments 1. A compound of Formula (I), or a pharmaceutically acceptable salt, solvate, or isomer thereof:wherein: R1is H, halogen, or straight-chain alkyl or alkoxyl having 1 to 6 carbon atoms; L is -C-C- or -C=C-;ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION X is C or N; Y is C, C(=O), S(=O)-O, or O-S(=O); Z is NHOH or a C2-C12ester; and n is an integer from 2 to 11. 2. The compound of embodiment 1, or a pharmaceutically acceptable salt, solvate, or isomer thereof, wherein one or more hydrogen atoms in R1are optionally replaced by F, or R1is H or Cl. 3. The compound of embodiment 1 or 2, or a pharmaceutically acceptable salt, solvate, or isomer thereof, wherein L is -C=C-. 4. The compound of any one of embodiments 1 to 3, or a pharmaceutically acceptable salt, solvate, or isomer thereof, wherein the compound of Formula (I) is selected from the group of the compounds of Formulae (Ia) and (Ib):a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, and (Ib),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof,ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION wherein X, Y, Z, and n have the meaning as indicated in embodiment 1. The compound of embodiment 4, or a pharmaceutically acceptable salt, solvate, or isomer thereof, wherein the compound of Formula (Ia) is selected from the group of the compounds of Formulae (Ia.1) and (Ia.2):a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, anda pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, wherein Y, Z, and n have the meaning as indicated in embodiment 1. The compound of Formula (I) according to embodiment 4, or a pharmaceutically acceptable salt, solvate, or isomer thereof, wherein the compound of Formula (Ib) is selected from the group of the compounds of Formulae (Ib.1) and (Ib.2):ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION (Ib.1),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, and (Ib.2),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, wherein Y, Z, and n have the meaning as indicated in embodiment 1. 7. The compound of any one embodiments 1 to 6, a pharmaceutically acceptable salt, solvate, or isomer thereof, wherein Y is C or C(=O). 8. The compound of embodiment 5, or a pharmaceutically acceptable salt, solvate, or isomer thereof, wherein the compound of Formula (Ia.1) is selected from the group of the compounds of Formulae (Ia.1.1) and (Ia.1.2)or a pharmaceutically acceptable salt, solvate, or isomer thereof,ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION (Ia.1.2),or a pharmaceutically acceptable salt, solvate, or isomer thereof, wherein Z and n have the meaning as indicated in embodiment 1. The compound of embodiment 5, or a pharmaceutically acceptable salt, solvate, or isomer thereof, wherein the compound of Formula (Ia.2) is selected from the group of the compounds of Formulae (Ia.2.1) and (Ia.2.2): (Ia.2.1),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, and (Ia.2.2),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, wherein Z and n have the meaning as indicated in embodiment 1.ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION The compound of embodiment 6, or a pharmaceutically acceptable salt, solvate, or isomer thereof, wherein the compound of Formula (Ib.1) is selected from the group of the compounds of Formulae (Ib.1.1) and (Ib.1.2): (Ib.1.1),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, and (Ib.1.2),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, wherein Z and n have the meaning as indicated in embodiment 1. The compound of embodiment 6, or a pharmaceutically acceptable salt, solvate, or isomer thereof, wherein the compound of Formula (Ib.2) is selected from the group of the compounds of Formulae (Ib.2.1) and (Ib.2.2): (Ib.2.1),ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, anda pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, wherein Z and n have the meaning as indicated in embodiment 1. The compound of any one of embodiments 1 to 11, or a pharmaceutically acceptable salt, solvate, or isomer thereof, wherein Z is NHOH. The compound of any one of embodiments 1 to 12, or a pharmaceutically acceptable salt, solvate, or isomer thereof, for use in treating a disease or disorder selected from the group consisting of liver cancer, oral cancer, ovarian cancer, bladder cancer, lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, and gastric cancer. The compound of any one of embodiments 1 to 13, or a pharmaceutically acceptable salt, solvate, or isomer thereof, for use in inhibiting the proliferation of a cell selected from the group consisting of HepG2, OML-1, MOC2, A2780, Kuramochi, UMUC3, J82, BFTC 905, A549, H460, MCF-7, MDA-MB231, PC3, 22RV1, BxPC3, SW1990, HT-29, DLD-1, AGS, and MKN45. A pharmaceutical composition comprising at least one compound of Formula (I) according to any one of embodiments 1 to 14, or a pharmaceutically acceptable salt, solvate, or isomer thereof, and a pharmaceutically acceptable carrier. A method of treating a disease or disorder, comprising administering to a subject a therapeutically effective amount of at least one compound of Formula (I) according toATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION any one of embodiments 1 to 14, or a pharmaceutically acceptable salt, solvate, or isomer thereof, or a pharmaceutical composition according to embodiment 15. 17. The method of embodiment 16, wherein the disease or disorder is selected from the group consisting of liver cancer, oral cancer, ovarian cancer, bladder cancer, lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, and gastric cancer. 18. A method of inhibiting the proliferation of a cell, comprising exposing a cell with an effective amount of at least one compound of Formula (I) according to any one of embodiments 1 to 14, or a pharmaceutically acceptable salt, solvate, or isomer thereof, or a pharmaceutical composition according to embodiment 15. 19. The method of embodiment 18, wherein the cell is selected from the group consisting of HepG2, OML-1, MOC2, A2780, Kuramochi, UMUC3, J82, BFTC 905, A549, H460, MCF-7, MDA-MB231, PC3, 22RV1, BxPC3, SW1990, HT-29, DLD-1, AGS, and MKN45. 20. Use of at least one compound of Formula (I) according to any one of embodiments 1 to 14, or a pharmaceutically acceptable salt, solvate, or isomer thereof, or a pharmaceutical composition according to embodiment 15, for use in treating a disease or disorder selected from the group consisting of liver cancer, oral cancer, ovarian cancer, bladder cancer, lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, and gastric cancer. 21. Use of at least one compound of Formula (I) according to any one of embodiments 1 to 14, or a pharmaceutically acceptable salt, solvate, or isomer thereof, or a pharmaceutical composition according to embodiment 15, for use in inhibiting the proliferation of a cell selected from the group consisting of HepG2, OML-1, MOC2, A2780, Kuramochi, UMUC3, J82, BFTC 905, A549, H460, MCF-7, MDA-MB231, PC3, 22RV1, BxPC3, SW1990, HT-29, DLD-1, AGS, and MKN45. 22. Use of at least one compound of Formula (I) according to any one of embodiments 1 to 14, or a pharmaceutically acceptable salt, solvate, or isomer thereof, or a pharmaceutical composition according to embodiment 15, for use in the manufacture of a medicament for treating a disease or disorder.ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION 23. The use of embodiment 22, comprising administering to a subject a therapeutically effective amount of at least one compound(s) of Formula (I) according to any one of embodiments 1 to 14, or a pharmaceutically acceptable salt, solvate, or isomer thereof, or a pharmaceutical composition according to embodiment 15. 24. The use of embodiment 23 or 24, wherein the disease or disorder is selected from the group consisting of liver cancer, oral cancer, ovarian cancer, bladder cancer, lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, and gastric cancer. EXAMPLES Example 1-Preparation of 4-(4-(5H-dibenzo[a,d][7]annulen-5- ylidene)piperidin-1-yl)-N-hydroxybutanamide (CYP-C4NHOH (6a)) Step 1: Preparation of ethyl 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)piperidine-1- carboxylate (CYP-COOEt (2)) Scheme 1Reagents and conditions: (a) ethyl acetate, 15% sodium hydroxide, room temperature, 24 hours; (b) toluene, ethyl chloroformate, 110°C, 48 hours. Reference: Bioorganic and Medicinal Chemistry Letters, 2015, vol.25, no.7, pp. 1436-1442.30 grams of cyproheptadine hydrochloride sesquihydrate (CYP-CH3 (1)) was placed in a 1-liter conical flask, 250 to 300 ml of ethyl acetate was added, and 240 ml of 15% sodium hydroxide aqueous solution was added. After stirring with a magnet at room temperature for 24 hours, water was added to remove water and salts by liquid phase-liquidATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION phase chromatography. The ethyl acetate layer was washed with 300 ml of water at least three times and a suitable amount of saturated salt water could be added. Anhydrous magnesium sulfate was used to remove excess water and the filtrate was collected by vacuum filtration. The filtrate was concentrated to obtain a white solid of cyproheptadine, which was redissolved in 300 ml of toluene and placed in a 500 ml round bottom flask.28.8 ml of ethyl chloroformate was added and heated to 110°C and stirred for 48 hours. The solid obtained by vacuum filtration was cyproheptadine, which could be recycled and reused. The filtrate was first concentrated to remove some of the toluene, and then 500 ml of ethyl acetate and 400 ml of water were used for liquid phase-liquid phase chromatography to remove toluene. The ethyl acetate layer was washed at least three times and a suitable amount of saturated salt water could be added. Anhydrous magnesium sulfate was used to remove excess water and the filtrate was collected by vacuum filtration. Concentration yielded CYP-COOEt (2) as an orange-white solid. CYP-COOEt (2)1H NMR (500 MHz, CDCl3): δ 7.33-7.31 (m, 4H), 7.25-7.22 (m, 2H), 7.18-7.16 (m, 2H), 6.91 (s, 2H, H-8, H-9), 4.13-4.09 (q, J = 7.1 Hz, H-3', 2H), 3.63 (m, 2H), 3.09-3.04 (m, 2H), 2.29-2.24 (m, 2H), 2.14-2.10 (m, 2H), 1.22 (t, J = 7.1 Hz, H-4', 3H).13C NMR (125 MHz, CDCl3): δ 155.47, 138.75, 134.81, 134.68, 134.44, 130.94, 128.26, 128.21, 127.86, 126.42, 61.23, 45.25, 29.94, 14.66. CYP-CH3(1): C21H21N, MW 287.40 (g / mol), cLogP 5.30, HPLC Purity 97%. CYP-COOEt (2): C23H23NO2, MW 345.43 (g / mol), cLogP 6.08, HPLC Purity 97%. Step 2: Preparation of 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)piperidine (CYP-H (3)) Scheme 2Reagents and conditions: (c) 95% ethanol, 10 M potassium hydroxide, 120°C, 72 hours.ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION Reference: Bioorganic and Medicinal Chemistry Letters, 2015, vol.25, no.7, p.1436- 1442.20 grams of CYP-COOEt (2) was placed in a 1-liter round-bottom flask and 400 ml of 95% ethanol was added. A 10 M potassium hydroxide solution was prepared (56.5 grams of potassium hydroxide was added to 100 ml of water and stirred until completely dissolved and placed in an ice bath). The 10 M potassium hydroxide was added to the round-bottom flask and heated to 120°C with magnetic stirring for 72 hours. Most of the ethanol was first removed using a concentrator and then liquid phase-liquid phase chromatography was performed to remove salts and water. The ethyl acetate layer was washed with 400 ml of water at least three times and a suitable amount of saturated salt water could be added. Anhydrous magnesium sulfate was used to remove excess water and the filtrate was collected by vacuum filtration. The filtrate was concentrated to obtain CYP-H (3) as a white solid. CYP-H (3)1H NMR (500 MHz, CDCl3): δ 7.343-7.315 (m, 4H), 7.257-7.224 (m, 2H), 7.215-7.200 (m, 2H), 6.930 (s, 2H), 2.931-2.887 (m, 2H), 2.693-2.645 (m, 2H), 2.300-2.248 (m, 2H), 2.123-2.077 (m, 2H).13C NMR (125 MHz, CDCl3): δ 139.58, 136.74, 135.24, 133.54, 131.41, 128.87, 128.61, 128.15, 126.60, 48.97, 32.35. CYP-H (3): C20H19N, MW 273.37 (g / mol), cLogP 4.86, HPLC Purity 97%. Step 3: Preparation of methyl 4-(4-(5H-dibenzo[a,d][7]annulen-5-ylidene)piperidin-1- yl)butanoate (CYP-C4OMe (5a)) Scheme 3Reagents and conditions: (d) dimethylformamide (DMF), anhydrous potassium carbonate (K2CO3), methyl 4-bromobutyrate, 80°C, 3 hours. 2 grams of CYP-H (3) was placed in a 100 ml round-bottom flask. For every 500 mg of CYP-H (3), 10 ml of dimethylformamide was added and stirred at room temperature until completely dissolved. First, 1.0 gram of anhydrous potassium carbonate was added, then 1.26ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION grams of methyl 4-bromobutyrate was added, and the reaction was carried out at 80°C for 3 to 5 hours. The reaction was monitored using TLC Silica gel 60 F254plates with ethyl acetate: hexane = 1:2 as the mobile phase. After the reaction was complete, liquid phase-liquid phase chromatography was performed to remove dimethylformamide (for every 500 mg of CYP-H (3) starting material, 100 ml of ethyl acetate was needed for chromatography). The ethyl acetate layer was washed with water at least three times and a suitable amount of saturated salt water could be added. Anhydrous magnesium sulfate was used to remove excess water, and the filtrate was collected by vacuum filtration. The filtrate was concentrated to obtain a crude product of CYP-C4OMe (5a), which was purified by column chromatography using Siliaflash® G60. The sample was redissolved in pure ethyl acetate and the compound was purified using ethyl acetate: hexane = 1:5 as the mobile phase. Finally, the solvent was removed to obtain CYP-C4OMe (5a) as a light orange liquid. CYP-C4OMe (5a): C25H27NO2, MW 373.48 (g / mol), cLogP 4.08, HPLC Purity 95%. Step 4: Preparation of CYP-C4NHOH (6a) Scheme 4Reagents and , (KOH), hydroxylamine hydrochloride (NH2OH∙HCl), room temperature, 15 hours. 5.71 grams of potassium hydroxide was placed in a conical flask and 12 ml of methanol was added.4.67 grams of hydroxylamine hydrochloride (NH2OH∙HCl) was placed in another conical flask and 24 ml of methanol was added and stirred for 1 hour. The potassium hydroxide solution was added to the other conical flask with a pipette and stirred at room temperature for 4 hours. The filtrate was collected by vacuum filtration and placed in a 100 ml round-bottom flask.1.27 grams of CYP-C4OMe (5a) was added, then 3.8 grams of potassium hydroxide was added and the reaction was carried out at room temperature for 15 to 17 hours. The solution was moved to a concentrator to remove methanol, and thenATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION dissolved in 200 to 250 ml of water. The pH of the solution was adjusted to 7 with acetic acid and tested with litmus paper. The solid was collected by vacuum filtration and washed with water. The solid was dried and collected to obtain CYP-C4NHOH (6a) as a white solid. CYP-C4NHOH (6a)1H NMR (500 MHz, DMSO-d6): δ 10.308 (s, 1H, NH), 8.620 (s, 1H, OH), 7.384-7.355 (m, 4H), 7.289-7.258 (m, 2H), 7.189-7.174 (m, 2H), 6.959 (s, 2H), 2.467-2.447 (m, 2H), 2.260-2.217 (m, 2H), 2.192 (t, J = 7.35 Hz, H-1', 2H), 2.079-2.047 (m, 2H), 1.956-1.917 (m, 4H), 1.595 (qui, J = 7.25 Hz, H-2', 2H).13C NMR (125 MHz, DMSO- d6): δ 169.32, 138.84, 136.05, 134.63, 132.58, 131.13, 128.54, 128.42, 128.17, 126.65, 57.24, 54.87, 30.65, 30.00, 22.82. CYP-C4NHOH (6a): C24H26N2O2, MW 374.48 (g / mol), cLogP 4.24, HPLC Purity 92%. Example 2-Preparation of 5-(4-(5H-dibenzo[a,d][7]annulen-5- ylidene)piperidin-1-yl)-N-hydroxypentanamide (CYP-C5NHOH (6b)) CYP-C5NHOH (6b) was prepared in a similar manner as described above for CYP- C4NHOH (6a), with the following exceptions: Step 3: Preparation of methyl 5-(4-(5H-dibenzo[a,d][7]annulen-5-ylidene)piperidin-1- yl)pentanoate (CYP-C5OMe (5b)) Scheme 5In Step 3, 1.26 grams of methyl 4-bromobutyrate used previously was replaced with 1.35 grams of methyl 5-bromopentanoate to obtain CYP-C5OMe (5b). CYP-C5OMe (5b): C26H29NO2, MW 387.51 (g / mol), cLogP 4.49, HPLC Purity 95%. Step 4: Preparation of CYP-C5NHOH (6b) Scheme 6ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATIONIn Step 4, 1.27 grams of CYP-C4OMe (5a) used previously was replaced with 1.31 grams of CYP-C5OMe (5b) to obtain CYP-C5NHOH (6b). CYP-C5NHOH (6b)1H NMR (500 MHz, DMSO-d6): δ 10.325 (s, 1H, NH), 8.656 (s, 1H, OH), 7.384-7.353 (m, 4H), 7.288-7.257 (m, 2H), 7.186-7.171 (m, 2H), 6.958 (s, 2H), 2.465 (m, 2H), 2.266-2.190 (m, 4H), 2.088-2.073 (m, 2H), 1.987-1.940 (m,2H), 1.919 (t, J = 7.45 Hz, H-4', 2H), 1.450 (qui, J = 7.10 Hz, H-3', 2H), 1.351 (sextet, J = 6.8 Hz, H-2', 2H).13C NMR (125 MHz, DMSO-d6): δ 169.52, 138.72, 135.72, 134.56, 132.66, 131.09, 128.50, 128.42, 128.19, 126.68, 57.38, 54.75, 32.28, 29.74, 25.94, 23.30. CYP-C5NHOH (6b): C25H28N2O2, MW 388.50 (g / mol), cLogP 4.07, HPLC Purity 98%. Example 3-Preparation of 6-(4-(5H-dibenzo[a,d][7]annulen-5- ylidene)piperidin-1-yl)-N-hydroxyhexanamide (CYP-C6NHOH (6c)) CYP-C6NHOH (6c) was prepared in a similar manner as described above for CYP- C4NHOH (6a), with the following exceptions: Step 3: Preparation of methyl 6-(4-(5H-dibenzo[a,d][7]annulen-5-ylidene)piperidin-1- yl)hexanoate (CYP-C6OMe (5c)) Scheme 7ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION

[0001] In Step 3, 1.26 grams of methyl 4-bromobutyrate used previously was replaced with 1.45 grams of methyl 6-bromohexanoate to obtain CYP-C6OMe (5c). CYP-C6OMe (5c): C27H31NO2, MW 401.54 (g / mol), cLogP 4.91, HPLC Purity 95%. Step 4: Preparation of CYP-C6NHOH (6c) Scheme 8In Step 4, 1.27 grams of CYP-C4OMe (5a) used previously was replaced with 1.36 grams of CYP-C6OMe (5c) to obtain CYP-C6NHOH (6c). CYPC6NHOH (6c)1H NMR (500 MHz, DMSO-d6): δ 10.308 (s, 1H, NH), 8.634 (s, 1H, OH), 7.378-7.348 (m, 4H), 7.282-7.253 (m, 2H), 7.181-7.166 (m, 2H), 6.961 (s, 2H), 2.465-2.455 (m, 2H), 2.251-2.168 (m, 4H), 2.087-2.071 (m, 2H), 1.970-1.941 (m, 2H), 1.904 (t, J = 7.25 Hz, 2H, H-5'), 1.456 (qui, J = 7.15 Hz, H-2', 2H), 1.372-1.330 (m, H-4', 2H), 1.227-1.176 (m, H-3', 2H).13C NMR (125 MHz, DMSO-d6): δ 168.98138.56, 135.86, 134.35, 132.25, 130.85, 128.26, 128.15, 127.88, 126.35, 57.58, 54.70, 32.20, 29.74, 26.54, 26.16, 25.02. CYP-C6NHOH (6c): C26H30N2O2, MW 402.53 (g / mol), cLogP 4.60, HPLC Purity 98%. Example 4-Preparation of 7-(4-(5H-dibenzo[a,d][7]annulen-5- ylidene)piperidin-1-yl)-N-hydroxyheptanamide (CYP-C7NHOH (6d)) CYP-C5NHOH (6b) was prepared in a similar manner as described above for CYP- C4NHOH (6a), with the following exceptions: Step 3: Preparation of methyl 7-(4-(5H-dibenzo[a,d][7]annulen-5-ylidene)piperidin-1- yl)heptanoate (CYP-C7OMe (5d)) Scheme 9ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATIONIn Step 3, 1.26 grams of methyl 4-bromobutyrate used previously was replaced with 1.55 grams of methyl 7-bromoheptanoate to obtain CYP-C7OMe (5d). CYP-C7OMe (5d): C28H33NO2, MW 415.56 (g / mol), cLogP 5.33, 95%. Step 4: Preparation of CYP-C7NHOH (6d) Scheme 10In Step 4, 1.27 grams of CYP-C4OMe (5a) used previously was replaced with 1.41 grams of CYP-C7OMe (5d) to obtain CYP-C7NHOH (6d). CYP-C7NHOH (6d)1H NMR (500 MHz, DMSO-d6): δ 10.313 (s, 1H, NH), 8.649 (s, 1H, OH), 7.388-7.359 (m, 4H), 7.293-7.263 (m, 2H), 7.195-7.180 (m, 2H), 6.962 (s, 2H), 2.538 (m, 2H), 2.282-2.250 (m, 4H), 2.183-2.136 (m, 2H), 1.996 (m, 2H), 1.908 (t, J = 7.35 Hz, H-6', 2H), 1.465-1.438 (m, H-2', 2H), 1.382 (m, H-5', 2H), 1.210 (m, H-3',4', 4H).13C NMR (125 MHz, DMSO-d6): δ 169.06138.43134.34130.85128.23128.19127.92126.43 57.4154.4532.1829.4028.42.26.5926.0625.03. CYP-C7NHOH (6d): C27H32N2O2, MW 416.56 (g / mol), cLogP 5.13, HPLC Purity 98%. Example 5-Preparation of 8-(4-(5H-dibenzo[a,d][7]annulen-5- ylidene)piperidin-1-yl)-N-hydroxyoctanamide (CYP-C8NHOH (6e)) CYP-C8NHOH (6e) was prepared in a similar manner as described above for CYP- C4NHOH (6a), with the following exceptions:ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION Step 3: Preparation of ethyl 8-(4-(5H-dibenzo[a,d][7]annulen-5-ylidene)piperidin-1- yl)octanoate (CYP-C8OEt (5e)) Scheme 11In Step 3, grams was replaced with 1.74 grams of ethyl 8-bromooctaoate to obtain CYP-C8OEt (5e). CYP-C8OEt (5e): C30H37NO2, MW 443.62 (g / mol), cLogP 6.08, HPLC Purity 95%. Step 4: Preparation of CYP-C8NHOH (6e) Scheme 12In grams was with 1.50 grams of CYP-C8OMe (5e) to obtain CYP-C8NHOH (6e). CYP-C8NHOH (6e)1H NMR (500 MHz, DMSO-d6): δ 10.311 (s, 1H, NH), 8.665 (s, 1H, OH), 7.377-7.347 (m, 4H), 7.282-7.252 (m, 2H), 7.181-7.166 (m, 2H), 6.953 (s, 2H), 2.467-2.447 (m, 2H), 2.251-2.173 (m, 2H), 2.081-2.064 (m, 4H), 1.971-1.942 (m, 2H), 1.903 (t, J = 7.30 Hz, H-7' 2H), 1.458-1.432 (m, H-2', 2H), 1.354 (m, H-6', 2H), 1.210 (m, H-3',4', 5', 6H).13C NMR (125 MHz, DMSO-d6): δ 169.02, 138.57, 135.87, 134.35, 132.24, 130.84, 138.27, 128.15, 127.87, 126.35, 57.67, 54.70, 32.21, 29.76, 28.60, 28.50, 26.85, 26.42, 25.03. CYP-C8NHOH (6e): C28H34N2O2, MW 430.58 (g / mol), cLogP 5.70, HPLC Purity 97%.ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION Example 6-Preparation of 10-(4-(5H-dibenzo[a,d][7]annulen-5- ylidene)piperidin-1-yl)-N-hydroxydecanamide (CYP-C10NHOH (6f)) CYP-C10NHOH (6f) was prepared in a similar manner as described above for CYP- C4NHOH (6a), with the following exceptions: Step 3: Preparation of methyl 10-(4-(5H-dibenzo[a,d][7]annulen-5-ylidene)piperidin- 1-yl)decanoate (CYP-C10OMe (5f)) Scheme 13In Step 3, grams was replaced with 1.84 grams of methyl 10-bromodecanoate to obtain CYP-C10OMe (5f). CYP-C10OMe (5f): C31H39NO2, MW 457.64 (g / mol), cLogP 6.58, HPLC Purity 95%. Step 4: Preparation of CYP-C10NHOH (6f) Scheme 14In Step 4, 1.27 grams of CYP-C4OMe (5a) used previously was replaced with 1.55 grams of CYP-C10OMe (5f) to obtain CYP-C10NHOH (6f). CYP-C10NHOH (6f)1H NMR (500 MHz, DMSO-d6): δ 10.297 (s, 1H, NH), 8.648 (s, 1H, OH), 7.381-7.351 (m, 4H), 7.285-7.255 (m, 2H), 7.185-7.170 (m, 2H), 6.955 (s, 2H), 2.476-2.468 (m, 2H), 2.265-2.191 (m, 4H), 2.100-2.069 (m, 2H), 1.984-1.941 (m, 2H),ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION 1.924-1.894 (t, H-9', 2H), 1.464-1.438 (m, H-2', 2H), 1.364-1.333 (m, H-8', 2H), 1.214 (m, H-3', 4', 5', 6', 7', 10H).13C NMR (125 MHz, DMSO-d6): δ 169.05, 138.54, 135.73, 134.35, 132.30, 130.84, 128.26, 128.15, 127.88, 126.36, 57.66, 54.66, 32.22, 29.69, 28.88, 28.67, 28.53, 26.96, 26.42, 25.07. CYP-C10NHOH (6f): C30H38N2O2, MW 458.63 (g / mol), cLogP 6.72, HPLC Purity 96%. Example 7-Preparation of 8-(4-(5H-dibenzo[a,d][7]annulen-5- ylidene)piperidin-1-yl)-N-hydroxyoctanamide hydrochloride (CYP- C8NHOH∙HCl (6e∙HCl)) Scheme 15Reagents and conditions: (f) acetonitrile (MeCN), concentrated hydrochloric acid (HCl), room temperature, 15 hours. 1.5 grams of CYP-C8NHOH (6e) was placed in a 250 ml round-bottom flask and 100 ml of acetonitrile was added. Under room temperature conditions, 3.81 grams of concentrated hydrochloric acid (approximately 3.2 ml) was slowly added with magnetic stirring. After stirring for 15 to 17 hours, the solid was filtered under vacuum and washed with acetonitrile. The solid was dried to obtain CYP-C8NHOH∙HCl (6e∙HCl) as a white solid. CYP- C8NHOH∙HCl (6e∙HCl): C28H35ClN2O2, MW 467.04 (g / mol), cLogP 6.08, HPLC Purity 98%. Example 8-Preparation of 4-(4-(5H-dibenzo[a,d][7]annulen-5- ylidene)piperidin-1-yl)-N-hydroxy-4-oxobutanamide (CYP-OC4NHOH (8a)) Step 1: Preparation of methyl 4-(4-(5H-dibenzo[a,d][7]annulen-5-ylidene)piperidin-1-yl)-4- oxobutanoate (CYP-OC4OMe (7a)) Scheme 16ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATIONReagents and , potassium carbonate (K2CO3), methyl 4-chloro-4-oxobutanoate, 80°C, 3 hours. 2 grams of CYP-H (3), prepared according to Example 1, Steps 1 and 2, was placed in a 100 ml round-bottom flask and 40 ml of dimethylformamide was added. The mixture was stirred at room temperature until completely dissolved. First, 5 drops of triethylamine were added, then 1.04 grams of methyl 4-chloro-4-oxobutanoate was added, and the reaction was carried out at 80°C for 3 to 5 hours. The reaction was monitored using TLC Silica gel 60 F254plates with ethyl acetate: hexane = 1:2 as the mobile phase. After the reaction was complete, liquid phase-liquid phase chromatography was performed to remove dimethylformamide (for every 500 mg of CYP-H (3) starting material, 100 ml of ethyl acetate was needed for chromatography). The ethyl acetate layer was washed with water containing sodium bicarbonate at least three times and a suitable amount of saturated salt water could be added. Anhydrous magnesium sulfate was used to remove excess water, and the filtrate was collected by vacuum filtration. The filtrate was concentrated to obtain a crude product of CYP-OC4OMe (7a), which was purified by column chromatography using Siliaflash® G60. The sample was redissolved in ethyl acetate, and the compound was purified using ethyl acetate: hexane = 1:5 as the mobile phase. Finally, the solvent was removed under reduced pressure to obtain CYP-OC4OMe (7a) as a light orange liquid. CYP-OC4OMe (7a): C25H25NO3, MW 387.47 (g / mol), cLogP 3.18, HPLC Purity 95%. Step 2: Preparation of CYP-OC4NHOH (8a) Scheme 17ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATIONReagents and , (KOH), hydroxylamine hydrochloride (NH2OH∙HCl), room temperature, 15 hours. 5.71 grams of potassium hydroxide was placed in a conical flask and 12 ml of methanol was added.4.67 grams of hydroxylamine hydrochloride (NH2OH∙HCl) was placed in another conical flask and 24 ml of methanol was added and stirred for 1 hour. The potassium hydroxide solution was added to the other conical flask with a pipette and stirred at room temperature for 4 hours. The filtrate was collected by vacuum filtration and placed in a 100 ml round-bottom flask.1.31 grams of CYP-OC4OMe (7a) was added, then 20 equivalents of potassium hydroxide were added and the reaction was carried out at room temperature for 15 to 17 hours. The solution was moved to a concentrator to remove methanol, and then dissolved in 200 to 250 ml of water. The pH of the solution was adjusted to 7 with acetic acid and tested with litmus paper. The solid was collected by vacuum filtration and washed with water. The solid was dried and collected to obtain CYP- OC4NHOH (8a) as a white solid. CYP-OC4NHOH (8a)1H NMR (500 MHz, DMSO-d6): δ 7.404-7.376 (m, 4H), 7.294-7.279 (m, 2H), 7.241-7.226 (m, 2H), 6.975 (s, 2H), 3.599-3.564 (m, 2H), 3.228-3.160 (m,2H), 2.400 (t, J = 6.55, 2H), 2.317-2.274 (m,1H), 2.228-2.175 (m,1H), 2.000-1.970 (m,1H), 1.924-1.876 (m,1H).13C NMR (125 MHz, DMSO-d6): δ 174.01, 169.49, 138.29, 138.25, 134.32, 134.24, 133.88, 130.93, 130.88, 128.29, 128.10, 126.63, 45.86, 42.62, 30.10, 29.42, 29.06, 27.44. CYP-OC4NHOH (8a): C24H24N2O3, MW 388.46 (g / mol), cLogP 3.19, HPLC Purity 95%. Example 9-Preparation of 5-(4-(5H-dibenzo[a,d][7]annulen-5- ylidene)piperidin-1-yl)-N-hydroxy-5-oxopentanamide (CYP-OC5NHOH (8b)) CYP-OC5NHOH (8b) was prepared in a similar manner as described above for CYP- OC4NHOH (8a), with the following exceptions:ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION Step 1: Preparation of methyl 5-(4-(5H-dibenzo[a,d][7]annulen-5-ylidene)piperidin-1- yl)-5-oxopentanoate (CYP-OC5OMe (7b)) Scheme 18In Step 1, 1.04 grams of methyl 4-chloro-4-oxobutanoate used previously was replaced with 1.28 grams of methyl 5-chloro-5-oxopentanoate to obtain CYP-OC5OMe (7b). CYP-OC5OMe (7b): C26H27NO3, MW 401.49 (g / mol), cLogP 3.59, HPLC Purity 95%. Step 4: Preparation of CYP-OC5NHOH (8b) Scheme 19In Step 2, 1.31 grams of CYP-OC4OMe (7a) used previously was replaced with 1.36 grams of CYP-OC5OMe (7b) to obtain CYP-OC5NHOH (8b). CYP-OC5NHOH (8b)1H NMR (500 MHz, DMSO-d6): δ 10.321 (s, 1H, NH), 8.638 (s, 1H, OH), 7.406-7.377 (m, 4H), 7.310-7.280 (m, 2H), 7.233-7.221 (m, 2H), 6.976 (s, 2H), 3.614-3.578 (m,1H), 3.534-3.507 (m,1H), 3.202-3.161 (m,2H), 2.304-2.180 (m,4H), 1.996-1.889 (m,4H), 1.684 (qui, J = 7.30 Hz, H-3', 2H).13C NMR (125 MHz, DMSO-d6): δ 169.97, 168.84, 138.21, 138.18, 134.26, 133.75, 130.88, 130.83, 128.24, 128.03, 127.99, 126.57, 46.01, 42.37, 31.63, 31.56, 30.24, 29.42, 20.92. CYP-OC5NHOH (8b): C25H26N2O3, MW 402.49 (g / mol), cLogP 3.36, HPLC Purity 98%.ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION Example 10-Preparation of 6-(4-(5H-dibenzo[a,d][7]annulen-5- ylidene)piperidin-1-yl)-N-hydroxy-6-oxohexanamide (CYP-OC6NHOH (8c))

[0002] CYP-OC6NHOH (8c) was prepared in a similar manner as described above for CYP- OC4NHOH (8a), with the following exceptions: Step 1: Preparation of methyl 6-(4-(5H-dibenzo[a,d][7]annulen-5-ylidene)piperidin-1- yl)-6-oxohexanoate (CYP-OC6OMe (7c)) Scheme 20In Step 1, grams was replaced with 1.24 grams of methyl 6-chloro-6-oxohexanoate to obtain CYP-OC6OMe (7c). CYP-OC6OMe (7c): C27H29NO3, MW 415.52 (g / mol), cLogP 4.01, HPLC Purity 95%. Step 4: Preparation of CYP-OC6NHOH (8c) Scheme 21In Step 2, grams was with 1.40 grams of CYP-OC6OMe (7c) to obtain CYP-OC6NHOH (8c). CYP-OC6NHOH (8c)1H NMR (500 MHz, DMSO-d6): δ 10.326 (s, 1H, NH), 8.653 (s, 1H, OH), 7.416-7.387 (m, 4H), 7.321-7.291 (m, 2H), 7.244-7.229 (m, 2H), 6.987 (s, H-8, H-9, 2H), 3.634-3.587 (m, 1H), 3.567-3.521 (m, 1H), 3.226-3.157 (m, 2H), 2.316-2.184 (m,ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION 4H), 1.973-1.893 (m, 4H), 1.485-1.436 (m, H-3', 4' 4H).13C NMR (125 MHz, DMSO-d6): δ 170.00, 168.65, 137.94, 137.90, 133.99, 133.46, 130.59, 130.53, 127.94, 127.74, 127.68, 126.27, 45.80, 41.07, 31.79, 31.72, 30.01, 29.14, 24.55, 24.12. CYP-OC6NHOH (8c): C26H28N2O3, MW 416.51 (g / mol), cLogP 2.67, HPLC Purity 97%. Example 11-Preparation of 7-(4-(5H-dibenzo[a,d][7]annulen-5- ylidene)piperidin-1-yl)-N-hydroxy-7-oxoheptanamide (CYP-OC7NHOH (8d)) CYP-OC7NHOH (8d) was prepared in a similar manner as described above for CYP- OC4NHOH (8a), with the following exceptions: Step 1: Preparation of methyl 7-(4-(5H-dibenzo[a,d][7]annulen-5-ylidene)piperidin-1- yl)-7-oxoheptanoate (CYP-OC7OMe (7d)) Scheme 22In Step 1, 1.04 grams of methyl 4-chloro-4-oxobutanoate used previously was replaced with 1.53 grams of methyl 7-chloro-7-oxoheptanoate to obtain CYP-OC7OMe (7d). CYP-OC7OMe (7d): C28H31NO3, MW 429.55 (g / mol), cLogP 4.43, HPLC Purity 95%. Step 4: Preparation of CYP-OC7NHOH (8d) Scheme 23ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION In Step 2, 1.31 grams of CYP-OC4OMe (7a) used previously was replaced with 1.46 grams of CYP-OC7OMe (7d) to obtain CYP-OC7NHOH (8d). CYP-OC7NHOH (8d)1H NMR (500 MHz, DMSO-d6): δ 10.317 (s, 1H, NH), 8.661 (s, 1H, OH), 7.407-7.378 (m, 4H), 7.312-7.282 (m, 2H), 7.234-7.224 (m, 2H), 6.978 (s, 2H), 3.612-3.576 (m, 1H), 3.546-3.521 (m, 1H), 3.210-3.161 (m, 2H), 2.296-2.174 (m, 4H), 1.958-1.897 (m, 4H), 1.494-1.419 (m, H- 3', 5', 4H), 1.245-1.200 (m, H-4', 2H).13C NMR (125 MHz, DMSO-d6): δ 138.22, 138.18, 134.29, 133.71, 130.87, 130.82, 128.23, 128.02, 127.97, 126.55, 46.07, 42.35, 32.21, 32.16, 30.29, 29.44, 28.34, 24.97, 24.56. CYP- OC7NHOH (8d): C27H30N2O3, MW 430.54 (g / mol), cLogP 3.20, HPLC Purity 98%. Example 12-Preparation of 8-(4-(5H-dibenzo[a,d][7]annulen-5- ylidene)piperidin-1-yl)-N-hydroxy-8-oxooctanamide (CYP-OC8NHOH (8e)) CYP-OC8NHOH (8e) was prepared in a similar manner as described above for CYP- OC4NHOH (8a), with the following exceptions: Step 1: Preparation of methyl 8-(4-(5H-dibenzo[a,d][7]annulen-5-ylidene)piperidin-1- yl)-8-oxooctanoate (CYP-OC8OMe (7e)) Scheme 24In Step 1, grams was replaced with 1.43 grams of methyl 8-chloro-8-oxooctanoate to obtain CYP-OC8OMe (7e). CYP-OC8OMe (7e): C29H33NO3, MW 443.57 (g / mol), cLogP 4.84, HPLC Purity 95%. Step 4: Preparation of CYP-OC8NHOH (8e) Scheme 25ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATIONIn grams was with 1.50 grams of CYP-OC8OMe (7e) to obtain CYP-OC8NHOH (8e). CYP-OC8NHOH (8e)1H NMR (500 MHz, DMSO-d6): δ 10.302 (s, 1H, NH), 8.630 (s, 1H, OH), 7.401-7.372 (m, 4H), 7.306-7.276 (m, 2H), 7.229-7.214 (m, 2H), 6.972 (s, 2H), 3.619-3.573 (m, 1H), 3.552-3.506 (m, 1H), 3.209-3.139 (m, 2H), 2.297-2.167 (m, 4H), 1.971-1.893 (m, 4H), 1.460-1.447 (m, H- 3', 6', 4H), 1.225-1.211 (m, H-4', 5', 4H).13C NMR (125 MHz, DMSO-d6): δ 170.31, 168.98, 138.11, 138.08, 134.16, 133.62, 130.76, 130.70, 128.12, 127.91, 127.86, 126.44, 45.96, 42.23, 32.16, 32.10, 30.19, 29.32, 28.35, 28.30, 24.88, 24.62. CYP-OC8NHOH (8e): C28H32N2O3, MW 444.57 (g / mol), cLogP 3.73, HPLC Purity 97%. Example 13-Preparation of 10-(4-(5H-dibenzo[a,d][7]annulen-5- ylidene)piperidin-1-yl)-N-hydroxy-10-oxodecanamide (CYP-OC10NHOH (8f)) CYP-OC10NHOH (8f) was prepared in a similar manner as described above for CYP- OC4NHOH (8a), with the following exceptions: Step 1: Preparation of methyl 10-(4-(5H-dibenzo[a,d][7]annulen-5-ylidene)piperidin- 1-yl)-10-oxodecanoate (CYP-OC10OMe (7f)) Scheme 26ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION In Step 1, 1.04 grams of methyl 4-chloro-4-oxobutanoate used previously was replaced with 1.89 grams of methyl 10-chloro-10-oxodecanoate to obtain CYP-OC10OMe (7f). CYP-OC10OMe (7f): C31H37NO3, MW 471.63 (g / mol), cLogP 5.68, HPLC Purity 95%. Step 2: Preparation of CYP-OC10NHOH (8f) Scheme 27grams was 1.60 grams of CYP-OC10OMe (7f) to obtain CYP-OC10NHOH (8f).

[0003] CYP-OC10NHOH (8f) 1H NMR (500 MHz, DMSO-d6): δ 10.322 (s, 1H, NH), 8.658 (s, 1H, OH), 7.406-7.377 (m, 4H), 7.311-7.281 (m, 2H), 7.233-7.221 (m, 2H), 6.977 (s, 2H), 3.620-3.574 (m, 1H), 3.546-3.510 (m, 1H), 3.207-3.143 (m, 2H), 2.298-2.170 (m, 4H), 1.972-1.898 (m, 4H), 1.454 (m, H- 3', 8', 4H), 1.220 (m, H-4', 5', 6', 7', 8H).13C NMR (125 MHz, DMSO-d6): δ 170.49, 169.12, 138.24, 138.20, 134.30, 133.75, 130.90, 130.84, 128.26, 128.06, 128.01, 126.59, 46.10, 42.37, 32.35, 32.25, 30.33, 29.46, 28.79, 28.67, 28.55, 25.11, 24.88. CYP-OC10NHOH (8f): C30H36N2O3, MW 472.62 (g / mol), cLogP 4.79, HPLC Purity 96%. Example 14-Preparation of 4-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2- b]pyridin-11(6H)-ylidene)piperidin-1-yl)-N-hydroxybutanamide (DESC4NHOH (10a)) Step 1: Preparation of methyl 4-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)- ylidene)piperidin-1-yl)butanoate (DESC4OMe (9a)) Scheme 28ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATIONcarbonate, methyl 4-bromobutyrate, 80°C, 3 hours. 2 grams of desloratadine was placed in a 100 ml round bottom flask, 40 ml of dimethylformamide was added, and stirred with a magnet at room temperature until completely dissolved. First, 0.88 grams of anhydrous potassium carbonate was added, followed by 1.10 grams of methyl 4-bromobutyrate, and the mixture was reacted at 80°C for 3 to 5 hours. The reaction was monitored by TLC Silica gel 60 F254plate with ethyl acetate: methanol = 5:1 as the mobile phase. After the reaction was complete, liquid phase-liquid phase chromatography was performed to remove dimethylformamide.400 ml of ethyl acetate was added along with 300 ml of water. The ethyl acetate layer was washed at least three times with water and a suitable amount of saturated salt water could be added. Anhydrous magnesium sulfate was used to remove excess water and the filtrate was collected by vacuum filtration. The filtrate was concentrated to obtain DESC4OMe (9a) as a crude product. The compound was purified by Siliaflash® G60 column chromatography method, with ethyl acetate: methanol = 5:1 as the mobile phase. Finally, the solvent was removed to obtain DESC4OMe (9a) as a light orange liquid. Step 2: Preparation of DESC4NHOH (10a) Scheme 29ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION Reagents and conditions: (j) methanol, potassium hydroxide, hydroxylamine hydrochloride, room temperature, 15 hours. 5.71 grams of potassium hydroxide was placed in a conical flask and 12 ml of methanol was added.4.67 grams of hydroxylamine hydrochloride was placed in another conical flask and 24 ml of methanol was added and stirred with a magnet for 1 hour. The potassium hydroxide solution was added dropwise to the other conical flask, and stirred at room temperature for 4 hours. The mixture was filtered under vacuum. The filtrate was collected and transferred to a 100 ml round bottom flask and 1.39 grams of DESC4OMe (9a) was added along with 3.8 grams of potassium hydroxide and the mixture was reacted at room temperature for 15 to 17 hours. The solution was transferred to a concentration flask to remove methanol by a concentrator.200 to 250 ml of water was added to dissolve the mixture completely. The pH of the solution was adjusted to 7 with acetic acid and tested with litmus paper. The solid was collected by vacuum filtration and washed with water. The solid was dried and collected to obtain DESC4NHOH (10a) as a white solid. DESC4NHOH (10a)1H NMR (500 MHz, DMSO-d6): δ 10.34 (s, 1H, N-H), 8.66 (s, 1H, -OH), 8.32 (d, J = 4.7 Hz, 1H), 7.55 (d, J = 7.6 Hz, 1H), 7.28–7.27 (m, 1H), 7.20–7.16 (m, 2H), 7.05 (d, J = 8.2 Hz, 1H), 3.31–3.24 (m, 2H), 2.83–2.77 (m, 2H), 2.61 (m, 2H), 2.33– 2.26 (m, 2H), 2.23–2.14 (m, 4H), 2.07–2.04 (m, 2H), 1.95 (t, J = 7.3 Hz, 2H, H-3’), 1.62 (quin, J = 7.0 Hz, 2H, H-2’).13C NMR (125 MHz, DMSO-d6): δ 169.02, 157.20, 146.30, 140.06, 138.05, 137.95, 137.25, 133.19, 131.91, 131.41, 130.79, 128.92, 125.57, 122.23, 56.95, 54.28, 54.25, 31.06, 30.50, 30.43, 30.26, 22.53. Example 15-Preparation of 5-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2- b]pyridin-11(6H)-ylidene)piperidin-1-yl)-N-hydroxypentanamide (DESC5NHOH (10b)) DESC5NHOH (10b) was prepared in a similar manner as described above for DESC4NHOH (10a), with the following exceptions: : Preparation of methyl 5-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin- 11(6H)-ylidene)piperidin-1-yl)pentanoate (DESC5OMe (9b)) Scheme 30ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATIONIn Step 1, 1.10 grams of methyl 4-bromobutyrate used previously was replaced with 1.19 grams of methyl 5-bromovalerate to obtain DESC5OMe (9b). : Preparation of 5-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)- ylidene)piperidin-1-yl)-N-hydroxypentanamide (DESC5NHOH (10b)) Scheme 31

[0004] In Step 2, 1.39 grams of DESC4OMe (9a) used previously was replaced with 1.44 grams of DESC5OMe (9b) to obtain DESC5NHOH (10b). DESC5NHOH (10b)1H NMR (500 MHz, DMSO-d6): δ 10.31 (s, 1H, N-H), 8.63 (s, 1H, -OH), 8.33–8.32 (m, 1H), 7.56–7.55 (m, 1H), 7.28–7.27 (m, 1H), 7.20–7.16 (m, 2H), 7.06 (d, J = 8.2 Hz, 1H), 3.27–3.25 (m, 2H), 2.84–2.78 (m, 2H), 2.62–2.58 (m, 2H), 2.33–2.24 (m, 2H), 2.22–2.13 (m, 4H), 2.09–2.02 (m, 2H), 1.93 (t, J = 7.2 Hz, 2H, H-4’), 1.47 (quin, J = 7.0 Hz, 2H, H-3’), 1.37 (quin, J = 7.0 Hz, 2H, H-2’).13C NMR (125 MHz, DMSO-d6): δ 168.94, 157.21, 146.26, 140.02, 138.12, 137.94, 137.18, 133.14, 131.82, 131.36, 130.75, 128.87, 125.52, 122.17, 57.21, 54.35, 54.30, 32.04, 31.03, 30.56, 30.46, 25.94, 23.09. Example 16-Preparation of 6-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2- b]pyridin-11(6H)-ylidene)piperidin-1-yl)-N-hydroxyhexanamide (DESC6NHOH (10c)) DESC6NHOH (10c) was prepared in a similar manner as described above for DESC4NHOH (10a), with the following exceptions:ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION : Preparation of methyl 6-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin- 11(6H)-ylidene)piperidin-1-yl)hexanoate (DESC6OMe (9c)) Scheme 32In with 1.28 grams of methyl 6-bromohexanoate to obtain DESC6OMe (9c). Step 2: Preparation of 6-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)- ylidene)piperidin-1-yl)-N-hydroxyhexanamide (DESC6NHOH (10c)) Scheme 33In grams was 1.49 grams of DESC6OMe (9c) to obtain DESC6NHOH (10c). DESC6NHOH (10c)1H NMR (500 MHz, DMSO-d6): δ 10.31 (s, 1H, N-H), 8.65 (s, 1H, -OH), 8.33–8.32 (m, 1H), 7.56 (d, J = 7.6 Hz, 1H), 7.28 (m, 1H), 7.21–7.17 (m, 2H), 7.05 (d, J = 8.2 Hz, 1H), 3.30–3.24 (m, 2H), 2.84–2.78 (m, 2H), 2.63 (m, 2H), 2.31–2.23 (m, 2H), 2.20– 2.14 (m, 4H), 2.08 (m, 2H), 1.92 (t, J = 7.4 Hz, 2H, H-5’), 1.47 (quin, J = 7.4 Hz, 2H, H-4’), 1.40–1.38 (m, 2H, H-2’), 1.24–1.18 (m, 2H, H-3’).13C NMR (125 MHz, DMSO-d6): δ 169.02, 157.18, 146.30, 140.08, 137.94, 137.27, 133.20, 131.93, 131.41, 130.79, 128.93, 125.58, 122.24, 57.52, 54.34, 32.20, 31.05, 30.50, 26.53, 26.10, 25.01.ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION Example 17-Preparation of 7-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2- b]pyridin-11(6H)-ylidene)piperidin-1-yl)-N-hydroxyheptanamide (DESC7NHOH (10d)) DESC7NHOH (10d) was prepared in a similar manner as described above for DESC4NHOH (10a), with the following exceptions: : Preparation of methyl 7-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin- 11(6H)-ylidene)piperidin-1-yl)heptanoate (DESC7OMe (9d)) Scheme 34In Step 1, 1.10 grams of methyl 4-bromobutyrate used previously was replaced with 1.36 grams of methyl 7-bromoheptanoate to obtain DESC7OMe (9d). : Preparation of 7-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)- ylidene)piperidin-1-yl)-N-hydroxyheptanamide (DESC7NHOH (10d)) Scheme 35In Step 2, 1.39 grams of DESC4OMe (9a) used previously was replaced with 1.53 grams of DESC7OMe (9d) to obtain DESC7NHOH (10d). DESC7NHOH (10d)1H NMR (500 MHz, DMSO-d6): δ 10.33 (s, 1H, N-H), 8.67 (s, 1H, -OH), 8.33 (d, J = 4.2 Hz, 1H), 7.57 (d, J = 7.5 Hz, 1H), 7.29–7.28 (m, 1H), 7.21–7.17 (m,ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION 2H), 7.06 (d, J = 8.2 Hz, 1H), 3.33–3.29 (m, 2H), 2.84–2.79 (m, 2H), 2.63–2.59 (m, 2H), 2.33– 2.26 (m, 2H), 2.23–2.14 (m, 4H), 2.09–2.04 (m, 2H), 1.92 (t, J = 7.3 Hz, 2H, H-6’), 1.47–1.45 (m, 2H, H-5’), 1.38 (m, 2H, H-2’), 1.23–1.22 (m, 4H, H-3’,4’).13C NMR (125 MHz, DMSO- d6): δ 169.10, 157.27, 146.33, 140.09, 138.22, 137.99, 137.29, 133.24, 131.86, 131.43, 130.85, 128.96, 125.61, 122.27, 57.69, 54.46, 54.41, 32.22, 31.09, 30.60, 30.52, 28.52, 26.74, 26.40, 25.10. -Preparation of 8-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)- ylidene)piperidin-1-yl)-N-hydroxyoctanamide (DESC8NHOH (10e)) DESC8NHOH (10e) was prepared in a similar manner as described above for DESC4NHOH (10a), with the following exceptions: : Preparation of ethyl 8-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)- ylidene)piperidin-1-yl)octanoate (DESC8OEt (9e)) Scheme 36In grams was with 1.53 grams of ethyl 8-bromooctanoate to obtain DESC8OEt (9e). : Preparation of 8-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)- ylidene)piperidin-1-yl)-N-hydroxyoctanamide (DESC8NHOH (10e)) Scheme 37ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATIONgrams was grams of DESC8OEt (9e) to obtain DESC8NHOH (10e). DESC8NHOH (10e)1H NMR (500 MHz, DMSO-d6): δ 10.31 (s, 1H, N-H), 8.64 (s, 1H, -OH), 8.32 (dd, J = 4.8, 1.3 Hz 1H), 7.56 (d, J = 7.7 Hz, 1H), 7.28 (m, 1H), 7.20–7.16 (m, 2H), 7.06 (d, J = 8.2 Hz, 1H), 3.31–3.24 (m, 2H), 2.84–2.78 (m, 2H), 2.63 (m, 2H), 2.33–2.25 (m, 2H), 2.20–2.14 (m, 4H), 2.10 (m, 2H), 1.91 (t, J = 7.4 Hz, 2H, H-7’), 1.45 (quin, J = 6.9 Hz, 2H, H-6’), 1.39 (m, 2H, H-2’), 1.22 (m, 6H, H-3’,4’,5’).13C NMR (125 MHz, DMSO-d6): δ 169.09, 157.19, 146.30, 140.08, 137.94, 137.27, 133.21, 131.42, 130.79, 128.92, 125.58, 122.25, 57.58, 54.31, 32.21, 31.05, 30.50, 28.59, 28.50, 26.83, 26.30, 25.04. -Preparation of 10-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)- ylidene)piperidin-1-yl)-N-hydroxydecanamide (DESC10NHOH (10f)) DESC10NHOH (10f) was prepared in a similar manner as described above for DESC4NHOH (10a), with the following exceptions: : Preparation of methyl 10-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin- 11(6H)-ylidene)piperidin-1-yl)decanoate (DESC10OMe (9f)) Scheme 38In grams was with 1.62 grams of methyl 10-bromodecanoate to obtain DESC10OMe (9f).ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION : Preparation of 10-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)- ylidene)piperidin-1-yl)-N-hydroxydecanamide (DESC10NHOH (10f)) Scheme 39grams was grams of DESC10OMe (9f) to obtain n DESC10NHOH (10f). DESC10NHOH (10f)1H NMR (500 MHz, DMSO-d6): δ 10.30 (s, 1H, N-H), 8.63 (s, 1H, -OH), 8.33–8.32 (m, 1H), 7.56 (d, J = 6.7 Hz, 1H), 7.29–7.28 (m, 1H), 7.21–7.17 (m, 2H), 7.06 (d, J = 8.2 Hz, 1H), 3.29–3.24 (m, 2H), 2.84–2.78 (m, 2H), 2.63 (m, 2H), 2.36–2.30 (m, 2H), 2.21–2.15 (m, 4H), 2.09 (m, 2H), 1.91 (t, J = 7.3 Hz, 2H, H-9’), 1.47–1.42 (m, 2H, H-8’), 1.40 (m, 2H, H-2’), 1.23 (m, 10H, H-3’,4’,5’,6’,7’).13C NMR (125 MHz, DMSO-d6): δ 169.07, 157.13, 146.30, 140.09, 137.91, 137.28, 133.21, 131.43, 130.77, 128.92, 125.58, 122.25, 57.64, 54.25, 32.22, 31.03, 30.93, 30.50, 28.87, 28.67, 28.53, 26.92, 25.08. Example 18-Preparation of 12-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2- b]pyridin-11(6H)-ylidene)piperidin-1-yl)-N-hydroxydodecanamide (DESC12NHOH (10g)) DESC12NHOH (10g) was prepared in a similar manner as described above for DESC4NHOH (10a), with the following exceptions: Step 1: Preparation of methyl 12-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2- b]pyridin-11(6H)-ylidene)piperidin-1-yl)dodecanoate (DESC12OMe (9g)) Scheme 40ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATIONgrams was with 1.79 grams of methyl 12-bromododecanoate to obtain DESC12OMe (9g). Step 2: Preparation of 12-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin- 11(6H)-ylidene)piperidin-1-yl)-N-hydroxydodecanamide (DESC12NHOH (10g)) Scheme 41grams was grams of DESC12OMe (9g) to obtain DESC12NHOH (10g). DESC12NHOH (10g)1H NMR (500 MHz, DMSO-d6): δ 10.31 (s, 1H, N-H), 8.64 (s, 1H, -OH), 8.32 (d, J = 4.5 Hz, 1H), 7.56 (d, J = 7.6 Hz, 1H), 7.28–7.27 (m, 1H), 7.20–7.16 (m, 2H), 7.05 (d, J = 8.2 Hz, 1H), 3.31–3.25 (m, 2H), 2.83–2.78 (m, 2H), 2.62 (m, 2H), 2.31–2.26 (m, 2H), 2.24–2.13 (m, 4H), 2.08 (m, 2H), 1.91 (t, J = 7.3 Hz, 2H, H-11’), 1.46–1.44 (m, 2H, H-10’), 1.38 (m, 2H, H-2’), 1.22 (m, 14H, H-3’,4’,5’,6’,7’,8’,9’).13C NMR (125 MHz, DMSO- d6): δ 169.07, 157.22, 146.31, 140.08, 137.96, 137.28, 133.22, 131.92, 131.42, 130.81, 128.93, 125.59, 122.25, 54.37, 48.59, 32.21, 31.06, 30.50, 28.94, 28.73, 28.56, 26.98, 26.40, 25.10. Example 19-Preparation of 4-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2- b]pyridin-11(6H)-ylidene)piperidin-1-yl)-N-hydroxy-4-oxobutanamide (DESOC4NHOH (12a))ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION Step 1: Preparation of methyl 4-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)- ylidene)piperidin-1-yl)-4-oxobutanoate (DESOC4OMe (11a)) Scheme 42succinyl chloride, 80°C, 3 hours. 2 grams of desloratadine was placed in a 100 ml round bottom flask, 40 ml of dimethylformamide was added, and stirred with a magnet at room temperature until completely dissolved. First, 5 drops of triethylamine were added, followed by 0.91 grams of methyl succinyl chloride, and the mixture was reacted at 80°C for 3 to 5 hours. The reaction was monitored by TLC Silica gel 60 F254plate with ethyl acetate: methanol = 5:1 as the mobile phase. After the reaction was complete, liquid phase-liquid phase chromatography was performed to remove dimethylformamide.400 ml of ethyl acetate was added along with 300 ml of alkaline water (each 500 ml of water should contain 1.2 grams of sodium bicarbonate). The ethyl acetate layer was washed at least three times with alkaline water and a suitable amount of saturated salt water could be added. Anhydrous magnesium sulfate was used to remove excess water and the filtrate was collected by vacuum filtration. The filtrate was concentrated to obtain DESOC4OMe (11a) as a crude product. The compound was purified by Siliaflash® G60 column chromatography method, with ethyl acetate: methanol = 5:1 as the mobile phase. Finally, the solvent was removed to obtain DESOC4OMe (11a) as a light orange liquid. Example 20-Preparation of 4-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2- b]pyridin-11(6H)-ylidene)piperidin-1-yl)-N-hydroxy-4-oxobutanamide (DESOC4NHOH (12a)) Scheme 43ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATIONReagents and conditions: (l) methanol, potassium hydroxide, hydroxylamine hydrochloride, room temperature, 15 hours. 5.71 grams of potassium hydroxide was placed in a conical flask and 12 ml of methanol was added.4.67 grams of hydroxylamine hydrochloride was placed in another conical flask and 24 ml of methanol was added and stirred with a magnet for 1 hour. The potassium hydroxide solution was added dropwise to the other conical flask, and stirred at room temperature for 4 hours. The mixture was filtered under vacuum, the filtrate was collected and transferred to a 100 ml round bottom flask and 1.44 grams of DESOC4OMe (11a) was added along with 3.8 grams of potassium hydroxide and the mixture was reacted at room temperature for 15 to 17 hours. The solution was transferred to a concentration flask to remove methanol by a concentrator.200 to 250 ml of water was added to dissolve the mixture completely. The pH of the solution was adjusted to 7 with acetic acid and tested with litmus paper. The solid was collected by vacuum filtration and washed with water, the solid was dried and collected to obtain DESOC4NHOH (12a) as a white solid. DESOC4NHOH (12a)1H NMR (500 MHz, DMSO-d6): δ 10.41 (s, 1H, N-H), 8.72 (s, 1H, -OH), 8.40–8.41 (m, 1H), 7.66 (d, J = 7.6 Hz, 1H), 7.38 (m, 1H), 7.29–7.24 (m, 2H), 7.18–7.14 (m, 1H), 3.88–3.84 (m, 1H), 3.72–3.65 (m, 1H), 3.36–3.33 (m, 2H), 3.23–3.17 (m, 1H), 2.91–2.87 (m, 2H), 2.48–2.35 (m, 2H), 2.29–2.22 (m, 2H), 2.04 (t, J = 7.2 Hz, 2H, H- 4’), 1.78–1.75 (m, 2H, H-3’).13C NMR (125 MHz, DMSO-d6): δ 170.02, 168.86, 156.75, 146.32, 140.16, 137.80, 137.45, 136.65, 133.33, 133.25, 131.58, 130.66, 128.91, 125.65, 122.37, 45.57, 42.02, 31.62, 31.58, 30.90, 30.17, 30.05, 20.88. Example 21-Preparation of 5-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2- b]pyridin-11(6H)-ylidene)piperidin-1-yl)-N-hydroxy-5-oxopentanamide (DESOC5NHOH (12b))ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION Step 1: Preparation of methyl 5-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin- 11(6H)-ylidene)piperidin-1-yl)-5-oxopentanoate (DESOC5OMe (11b)) Scheme 44Reagents and conditions: (m) acetonitrile, triethylamine, methyl 5-chloro-5- oxopentanoate, 80°C, 3 hours. 1.28 grams of methyl hydrogen glutarate was placed in a 50 ml round bottom flask, 20 ml of benzene was added, and stirred with a magnet. Then, 1.10 grams of thionyl chloride was added, and the mixture was reacted at 80°C for 3 hours. The solvent and thionyl chloride were removed by a concentrator to obtain methyl 5-chloro-5-oxopentanoate.2 grams of desloratadine was placed in a 250 ml round bottom flask, 120 ml of acetonitrile was added, and stirred with a magnet until completely dissolved.5 drops of triethylamine were added.5 ml of acetonitrile was used to dissolve methyl 5-chloro-5-oxopentanoate and added to the round bottom flask. The mixture was reacted at 80°C for 3 to 5 hours. The reaction was monitored by TLC Silica gel 60 F254plate with ethyl acetate: methanol = 5:1 as the mobile phase. After the reaction was complete, the mixture was filtered under vacuum, and the filtrate was collected (the solid desloratadine could be recycled and reused). The filtrate was concentrated to obtain DESOC5OMe (11b) as a crude product. The compound was purified by Siliaflash® G60 column chromatography method, with ethyl acetate: methanol = 5:1 as the mobile phase. Finally, the solvent was removed to obtain DESOC5OMe (11b) as a light orange liquid. Step 2: Preparation of 5-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)- ylidene)piperidin-1-yl)-N-hydroxy-5-oxopentanamide (DESOC5NHOH (12b)) Scheme 45ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATIONReagents and conditions: (n) methanol, potassium hydroxide, hydroxylamine hydrochloride, room temperature, 15 hours. 5.71 grams of potassium hydroxide was placed in a conical flask and 12 ml of methanol was added.4.67 grams of hydroxylamine hydrochloride was placed in another conical flask and 24 ml of methanol was added and stirred with a magnet for 1 hour. The potassium hydroxide solution was added dropwise to the other conical flask, and stirred at room temperature for 4 hours. The mixture was filtered under vacuum, the filtrate was collected and transferred to a 100 ml round bottom flask and 1.48 grams of DESOC5OMe (11b) was added along with 3.8 grams of potassium hydroxide and the mixture was reacted at room temperature for 15 to 17 hours. The solution was transferred to a concentration flask to remove methanol by a concentrator.200 to 250 ml of water was added to dissolve the mixture completely. The pH of the solution was adjusted to 7 with acetic acid and tested with litmus paper. The solid was collected by vacuum filtration and washed with water, the solid was dried and collected to obtain DESOC5NHOH (12b) as a white solid. DESOC5NHOH (12b)1H NMR (500 MHz, DMSO-d6): δ 10.39 (s, 1H, N-H), 8.70 (s, 1H, -OH), 8.41–8.40 (m, 1H), 7.64 (d, J = 7.6 Hz, 1H), 7.37 (m, 1H), 7.29–7.25 (m, 2H), 7.17–7.14 (m, 1H), 3.88–3.83 (m, 1H), 3.70–3.64 (m, 1H), 3.34–3.32 (m, 2H), 3.22–3.16 (m, 1H), 2.90–2.86 (m, 2H), 2.46–2.33 (m, 4H), 2.28–2.21 (m, 2H), 2.03 (t, J = 7.2 Hz, 2H, H- 4’), 1.78–1.75 (m, 2H, H-3’).13C NMR (125 MHz, DMSO-d6): δ 170.01, 168.83, 156.77, 146.34, 140.17, 137.83, 137.47, 136.62, 133.34, 133.24, 131.57, 130.68, 128.92, 125.66, 122.35, 45.55, 42.05, 31.61, 31.56, 30.93, 30.53, 30.15, 30.02, 20.90. Example 22-Preparation of 6-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2- b]pyridin-11(6H)-ylidene)piperidin-1-yl)-N-hydroxy-6-oxohexanamide (DESOC6NHOH (12c))ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION DESOC6NHOH (12c) was prepared in a similar manner as described above for DESOC4NHOH (12a), with the following exceptions: Step 1: Preparation of methyl 6-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin- 11(6H)-ylidene)piperidin-1-yl)-6-oxohexanoate (DESOC6OMe (11c)) Scheme 46In grams was with 1.09 grams of methyl adipoyl chloride to obtain DESOC6OMe (11c). Step 2: Preparation of 6-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)- ylidene)piperidin-1-yl)-N-hydroxy-6-oxohexanamide (DESOC6NHOH (12c)) Scheme 47In Step 2, 1.44 grams of DESOC4OMe (11a) used previously was replaced with 1.53 grams of DESOC6OMe (11c) to obtain DESOC6NHOH (12c). DESOC6NHOH (12c)1H NMR (500 MHz, DMSO-d6)：δ 10.32 (s, 1H, N-H), 8.64 (s, 1H, -OH), 8.35 (d, J = 4.7 Hz, 1H), 7.58 (d, J = 7.6 Hz, 1H), 7.31 (m, 1H), 7.23–7.19 (m, 2H), 7.12–7.09 (m, 1H), 3.82–3.77 (m, 1H), 3.67–3.60 (m, 1H), 3.36–3.33 (m, 2H), 3.17– 3.13 (m, 1H), 2.86–2.81 (m, 2H), 2.41–2.27 (m, 4H), 2.24–2.12 (m, 2H), 1.95 (t, J = 6.8 Hz, 2H, H-5’), 1.49 (m, 4H, H-3’,4’).13C NMR (125 MHz, DMSO-d6): δ 170.30, 168.85, 156.75,ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION 146.27, 140.13, 137.83, 137.75, 137.41, 136.61, 133.31, 133.20, 131.54, 130.63, 128.88, 125.62, 122.30, 45.59, 42.01, 32.03, 31.96, 30.90, 30.50, 30.14, 30.00, 24.80, 24.36. Example 23-Preparation of 7-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2- b]pyridin-11(6H)-ylidene)piperidin-1-yl)-N-hydroxy-7-oxoheptanamide (DESOC7NHOH (12d)) DESOC7NHOH (12d) was prepared in a similar manner as described above for DESOC5NHOH (12b), with the following exceptions: Step 1: Preparation of methyl 7-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin- 11(6H)-ylidene)piperidin-1-yl)-7-oxoheptanoate (DESOC7OMe (11d)) Scheme 48In Step 1, 1.28 grams of methyl hydrogen glutarate used previously was replaced with 1.34 grams of 7-methoxy-7-oxoheptanoic acid to obtain methyl 7-chloro-7-oxoheptanoate and DESOC7OMe (11d). Step 2: Preparation of 7-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)- ylidene)piperidin-1-yl)-N-hydroxy-7-oxoheptanamide (DESOC7NHOH (12d)) Scheme 49ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION In Step 2, 1.48 grams of DESOC5OMe (11b) used previously was replaced with 1.58 grams of DESOC7OMe (11d) to obtain DESOC7NHOH (12d). DESOC7NHOH (12d)1H NMR (500 MHz, DMSO-d6)：δ 10.31 (s, 1H, N-H), 8.64 (s, 1H, -OH), 8.34 (d, J = 4.5 Hz, 1H), 7.58 (d, J = 7.7 Hz, 1H), 7.31 (m, 1H), 7.22–7.19 (m, 2H), 7.11–7.08 (m, 1H), 3.81–3.76 (m, 1H), 3.66–3.59 (m, 1H), 3.27–3.24 (m, 2H), 3.15– 3.09 (m, 1H), 2.84–2.80 (m, 2H), 2.39–2.29 (m, 4H), 2.27–2.11 (m, 2H), 1.92 (t, J = 7.3 Hz, 2H, H-6’), 1.48–1.46 (m, 4H, H-3’,4’), 1.24–1.23 (m, 2H, H-5’).13C NMR (125 MHz, DMSO-d6): δ 170.39, 168.92, 156.77, 146.33, 140.16, 137.84, 137.77, 137.45, 136.67, 133.31, 133.24, 131.57, 130.68, 128.92, 125.65, 122.34, 45.66, 45.61, 42.03, 41.91, 32.19, 31.00, 30.93, 30.51, 30.17, 30.05, 28.33, 24.93, 24.53. Example 24-Preparation of 8-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2- b]pyridin-11(6H)-ylidene)piperidin-1-yl)-N-hydroxy-8-oxooctanamide (DESOC8NHOH (12e)) DESOC8NHOH (12e) was prepared in a similar manner as described above for DESOC4NHOH (12a), with the following exceptions: Step 1: Preparation of methyl 8-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin- 11(6H)-ylidene)piperidin-1-yl)-8-oxooctanoate (DESOC8OMe (11e)) Scheme 50In grams was with 1.25 grams of methyl 8-chloro-8-oxooctanoate to obtain DESOC8OMe (11e). Step 2: Preparation of 8-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)- ylidene)piperidin-1-yl)-N-hydroxy-8-oxooctanamide (DESOC8NHOH (12e)) Scheme 51ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATIONgrams was grams of DESOC8OMe (11e) to obtain DESOC8NHOH (12e). DESOC8NHOH (12e)1H NMR (500 MHz, DMSO-d6): δ 10.32 (s, 1H, N-H), 8.65 (s, 1H, -OH), 8.34 (d, J = 4.5 Hz, 1H), 7.56 (d, J = 7.6 Hz, 1H), 7.29 (m, 1H), 7.21–7.18 (m, 2H), 7.10–7.08 (m, 1H), 3.81–3.76 (m, 1H), 3.65–3.59 (m, 1H), 3.35–3.23 (m, 3H), 3.17– 3.09 (m, 1H), 2.83–2.79 (m, 2H), 2.39–2.24 (m, 4H), 2.23–2.11 (m, 2H), 1.92 (t, J = 7.3 Hz, 2H, H-7’), 1.47–1.45 (m, 4H, H-3’,6’), 1.24–1.23 (m, 2H, H-4’, 5’).13C NMR (125 MHz, DMSO-d6): δ 170.64, 169.18, 156.87, 146.40, 140.23, 137.90, 137.83, 137.57, 136.73, 133.37, 131.66, 130.78, 128.99, 125.74, 122.46, 45.74, 45.69, 42.10, 41.98, 32.34, 32.25, 31.07, 31.00, 30.58, 30.24, 30.11, 28.51, 28.46, 25.05, 24.80. Example 25-Preparation of 10-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2- b]pyridin-11(6H)-ylidene)piperidin-1-yl)-N-hydroxy-10-oxodecanamide (DESOC10NHOH (12f)) DESOC10NHOH (12f) was prepared in a similar manner as described above for DESOC5NHOH (12b), with the following exceptions: Step 1: Preparation of methyl 10-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2- b]pyridin-11(6H)-ylidene)piperidin-1-yl)-10-oxodecanoate (DESOC10OMe (11f)) Scheme 52ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION In Step 1, 1.28 grams of methyl hydrogen glutarate used previously was replaced with 1.66 grams of sebacic acid monomethyl ester to obtain methyl 10-chloro-10-oxodecanoate and DESOC10OMe (11f). Step 2: Preparation of 10-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin- 11(6H)-ylidene)piperidin-1-yl)-N-hydroxy-10-oxodecanamide (DESOC10NHOH (12f)) Scheme 53grams was grams of DESOC10OMe (11f) to obtain DESOC10NHOH (12f). DESOC10NHOH (12f)1H NMR (500 MHz, DMSO-d6): δ 10.30 (s, 1H, N-H), 8.63 (s, 1H, -OH), 8.34 (d, J = 4.4 Hz, 1H), 7.58 (d, J = 7.7 Hz, 1H), 7.30 (m, 1H), 7.22–7.19 (m, 2H), 7.11–7.08 (m, 1H), 3.82–3.76 (m, 1H), 3.66–3.59 (m, 1H), 3.28–3.26 (m, 2H), 3.16– 3.08 (m, 1H), 2.85–2.79 (m, 2H), 2.40–2.25 (m, 4H), 2.23–2.11 (m, 2H), 1.91 (t, J = 7.4 Hz, 2H, H-9’), 1.47–1.46 (m, 4H, H-3’,8’), 1.24–1.23 (m, 8H, H-4’, 5’,6’,7’).13C NMR (125 MHz, DMSO-d6): δ 170.51, 169.03, 156.81, 146.33, 140.17, 137.85, 137.46, 136.67, 133.32, 133.25, 131.57, 130.69, 128.92, 125.66, 122.35, 45.62, 42.03, 41.91, 32.30, 32.20, 31.01, 30.93, 30.52, 30.18, 30.05, 28.75, 28.62, 28.51, 25.07, 24.83. Example 26-Preparation of 12-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2- b]pyridin-11(6H)-ylidene)piperidin-1-yl)-N-hydroxy-12-oxododecanamide (DESOC12NHOH (12g)) DESOC12NHOH (12g) was prepared in a similar manner as described above for DESOC5NHOH (12b), with the following exceptions: Step 1: Preparation of methyl 12-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2- b]pyridin-11(6H)-ylidene)piperidin-1-yl)-12-oxododecanoate (DESOC12OMe (11g))ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION Scheme 54grams was with 1.87 grams of dodecanedioic acid monomethyl ester to obtain methyl 12-chloro-12- dodecanoate and DESOC12OMe (11g). Step 2: Preparation of 12-(4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin- 11(6H)-ylidene)piperidin-1-yl)-N-hydroxy-12-oxododecanamide (DESOC12NHOH (12g)) Scheme 55grams was grams of DESOC12OMe (11g) to obtain DESOC12NHOH (12g). DESOC12NHOH (12g)1H NMR (500 MHz, DMSO-d6): δ 10.31 (s, 1H, N-H), 8.64 (s, 1H, -OH), 8.34 (d, J = 4.5 Hz, 1H), 7.57 (d, J = 7.7 Hz, 1H), 7.31 (m, 1H), 7.22–7.19 (m, 2H), 7.10–7.08 (m, 1H), 3.82–3.75 (m, 1H), 3.66–3.59 (m, 1H), 3.29–3.23 (m, 2H), 3.15– 3.08 (m, 1H), 2.85–2.79 (m, 2H), 2.39–2.24 (m, 4H), 2.22–2.11 (m, 2H), 1.91 (t, J = 7.3 Hz, 2H, H-11’), 1.46 (m, 4H, H-3’,10’), 1.22 (m, 12H, H-4’, 5’,6’,7’,8’,9’).13C NMR (125 MHz, DMSO-d6): δ 170.51, 169.05, 156.82, 146.35, 146.31, 140.17, 137.86, 137.78, 137.47, 136.68, 133.33, 133.26, 131.58, 130.70, 128.93, 125.67, 125.63, 122.36, 45.67, 45.64, 42.04, 41.91, 32.32, 32.22, 31.03, 30.94, 30.53, 30.19, 30.06, 28.90, 28.88, 28.78, 28.70, 28.55, 25.08, 24.86.ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION Example 27: Inhibition Test of Cell Survival Rate in Cancer Cell Lines Cell Lines and Cell Culture Conditions: The cell lines used for the cell survival rate inhibition test include human liver cancer cell line HepG2, human oral cancer cell lines OML-1 and MOC2, human ovarian cancer cell lines A2780 and Kuramochi, human bladder cancer cell lines UMUC3, J82, and BFTC 905, human lung cancer cell lines A549 and H460, human breast cancer cell lines MCF-7 and MDA-MB231, human prostate cancer cell lines PC3 and 22RV1, human pancreatic cancer cell line BxPC3, human colorectal cancer cell line SW1990, HT-29, and DLD-1, and human gastric cancer cell lines AGS and MKN45. All cells were obtained from the Bioresource Collection and Research Center, Hsinchu, Taiwan. The human colorectal cancer cell lines SW1990, HT-29, and DLD-1, human ovarian cancer cell lines A2780 and Kuramochi were cultured in RPMI 1640 medium (HyClone, USA) supplemented with 10% fetal bovine serum (FBS, Gibco, Life Technologies, USA) and antibiotics (streptomycin 100mg / ml and penicillin 100U / ml, Gibco, Life Technologies, USA). The human bladder cancer cell lines UMUC3, J82, and BFTC 905, and human liver cancer cell line HepG2 were cultured in DMEM medium (HyClone, USA) supplemented with 10% FBS and antibiotics. The human oral cancer cell lines OML-1 and MOC2 were cultured in DMEM+F12 medium (HyClone, USA) supplemented with 10% FBS, 1% antibiotics, and 400ng / ml hydrocortisone. The human lung cancer cell lines A549 and H460, and human prostate cancer cell line 22RV1 were cultured in RPMI-1640 (ATCC modification) (A10491) medium supplemented with 10% FBS and 1% penicillin / streptomycin (P / S). The human breast cancer cell line MCF-7 was cultured in DMEM medium (12100) supplemented with 10% FBS, 1% P / S, 1% non-essential amino acids (NEAA), and 1% sodium pyruvate. The human breast cancer cell line MDA-MB231 was cultured in a mixture of DMEM medium and F12 in a ratio of 3:2, supplemented with 10% FBS and 1% P / S.ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION The human prostate cancer cell line PC3 was cultured in Ham's F-12K (Kaighn’s) (21127) medium supplemented with 10% FBS and 1% P / S. The human pancreatic cancer cell line BxPC3 was cultured in RPMI-1640 (PM150110) medium supplemented with 10% FBS and 1% P / S. The human gastric cancer cell lines AGS and MKN45 were cultured in RPMI-1640 medium supplemented with 10% FBS and 1% P / S. All cell lines were maintained in a carbon dioxide incubator (SANYO, Osaka, Japan) at 37ºC, under conditions of 5% CO2and 95% air. Example 28 : Cell Viability Inhibition Assay: Cell viability was assessed by staining with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl tetrazolium bromide) (Bionovas Biotechnology Co., Ltd., Toronto, Ontario, Canada). Cancer cells numbering 5×103to 1×104were cultured in a 96-well plate. After overnight growth, the cells were treated with different concentrations of cyproheptadine, the cyproheptadine derivatives according to the present disclosure, and comparative anticancer agents (suberoylanilide hydroxamic acid (SAHA or Vorinostat)), Paclitaxel (Taxol), 5- fluorouracil (5-FU), and Cisplatin) for 24 hours. After the treatment, MTT was added at a final concentration of 0.5mg / ml, and the cells were further cultured for 1.5 hours. After removing the medium, 200 μl DMSO (0.5%) was added and the absorbance at a wavelength of 570 nm was recorded on an ELISA plate reader (SpectraMax 340PC384, Molecular Devices, Orleans, California, USA). The cell inhibition ratio (%) was calculated using the following formula: Cell inhibition ratio (%) = [(Control group - Experimental group) / Control group] × 100%, Wherein Control group and Experimental group are the average absorbance values of three independent experiments for Control group and Experimental group, respectively. The concentration of the test compound required to inhibit tumor cell proliferation by 50% (IC50) was determined based on the dose-response curve with the concentration at points of 0, 5, 10, 15, 20, 50, and 100 µM, thereby determining the cell survival rate. All data are theATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION average values of three replicates of a single test, and the experiment was repeated at least three times. Results Table 2 shows the cytotoxicity results after various human cancer cell lines were treated with cyproheptadine, the cyproheptadine derivatives according to the present disclosure, and the comparative anticancer agents for 48 hours. Table 2 IC50(µM)ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION HT-29 Color 37.01 9.712 >100 <5 >10 >100Example 29: Mouse Tumor Assay The mice used in this example were of the strain C57BL / 6JNarl, male, obtained from the National Laboratory Animal Center, Taiwan. A total of 15 mice were used, all born on November 20, 2023. Tumor induction began on January 4, 2024 (18 days before the treatment began). The cell line used for tumor induction was MOC2 s.c. Tumor size and mice weight were recorded throughout the example. Treatment began on January 22, 2024 (day 1). Group 1 (Mice No.1-5): FIG.1A shows the tumor size of mice no.1-5 varying with treatment days from day 1 to day 22. FIG.1B shows the mice weights of mice no.1-5 varying with treatment days from day 1 to day 22. Mice no.1-5 were orally administered with water at a dosage of 30mg per kg of body weight, 5 times per week. Group 2 (Mice No.6-10): FIG.2A shows the tumor size of mice no.6-10 varying with treatment days from day 1 to day 22. FIG.2B shows the mice weights of mice no.6-10 varying with treatment days from day 1 to day 22. Mice no.6-10 were orally administered with CYP-C8NHOH∙HCl (6e∙HCl) at a dosage of 30mg per kg of body weight, 5 times per week. Group 3 (Mice No.11-15): FIG.3A shows the tumor size of mice no.11-15 varying with treatment days from day 1 to day 22. FIG.3B shows the mice weights of mice no.11-15 varying with treatment days from day 1 to day 22. Mice no.11-15 were injected with CYP- C8NHOH∙HCl (6e∙HCl) at a dosage of 30mg per kg of body weight, 5 times per week. This example demonstrates the potential therapeutic effects of the compound of Formula (I) on tumor growth in mice. The results suggest that the compound of Formula (I) may be a promising candidate for further development as an anti-cancer therapeutic.ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety. Where a term in the present application is found to be defined differently in a document incorporated herein by reference, the definition provided herein is to serve as the definition for the term. While the disclosure has been described in connection with specific embodiments thereof, it will be understood that the present disclosure is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the disclosure following, in general, the principles of the disclosure and including such departures from the present disclosure that come within known or customary practice within the art to which the disclosure pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the claims. Other embodiments are in the claims.

Claims

ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION CLAIMS What is claimed is:

1. A compound of Formula (I) or a pharmaceutically acceptable salt, solvate, or isomer thereof:wherein R1is H, halogen, or straight-chain alkyl or alkoxyl having 1 to 6 carbon atoms; L is -C-C- or -C=C-; X is C or N; Y is C, C(=O), S(=O)-O, or O-S(=O); Z is NHOH or a C2-C12ester; and n is an integer from 2 to 11.

2. The compound according to claim 1, wherein one or more hydrogen atoms in R1are optionally replaced by F, or R1is H or Cl.

3. The compound according to claim 1 or claim 2, wherein L is -C=C-.

4. The compound according to any one of claims 1 to 3, wherein the compound of Formula (I) is selected from the compounds of Formulae (Ia) and (Ib):ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, and (Ib),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof.

5. The compound according to claim 4, wherein the compound of Formula (Ia) is selected from the compounds of Formulae (Ia.1) and (Ia.2): (Ia.1),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, and (Ia.2),ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof.

6. The compound according to claim 4, wherein the compound of Formula (Ib) is selected from the compounds of Formulae (Ib.1) and (Ib.2): (Ib.1),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, and (Ib.2),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof,.

7. The compound according to any one claims 1 to 6, wherein Y is C or C(=O).

8. The compound according to claim 5, wherein the compound of Formula (Ia.1) is selected from the compounds of Formulae (Ia.1.1) and (Ia.1.2)ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION (Ia.1.1),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, and (Ia.1.2),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof.

9. The compound according to claim 5, wherein the compound of Formula (Ia.2) is selected from the compounds of Formulae (Ia.2.1) and (Ia.2.2): (Ia.2.1),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, andATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION (Ia.2.2),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof.

10. The compound according to claim 6, wherein the compound of Formula (Ib.1) is selected from the compounds of Formulae (Ib.1.1) and (Ib.1.2): (Ib.1.1),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, and (Ib.1.2),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof.ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION 11. The compound according to claim 6, wherein the compound of Formula (Ib.2) is selected from the compounds of Formulae (Ib.2.1) and (Ib.2.2): (Ib.2.1),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof, and (Ib.2.2),a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable isomer thereof.

12. The compound according to any one of claims 1 to 11, wherein Z is NHOH.

13. The compound according to any one of claims 1 to 12, for use in treating a disease or disorder selected from the group consisting of liver cancer, oral cancer, ovarian cancer, bladder cancer, lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, and gastric cancer.

14. The compound according to any one of claims 1 to 13, for use in inhibiting the proliferation of a cell selected from the group consisting of HepG2, OML-1, MOC2, A2780, Kuramochi, UMUC3, J82, BFTC 905, A549, H460, MCF-7, MDA-MB231, PC3, 22RV1, BxPC3, SW1990, HT-29, DLD-1, AGS, and MKN45.ATTORNEY DOCKET NO. S92667 / PC0505 INTERNATIONAL PATENT APPLICATION 15. A pharmaceutical composition comprising at least one compound of Formula (I) according to any one of claims 1 to 14, and a pharmaceutically acceptable carrier.

16. A method of treating a disorder, comprising administering to a subject a therapeutically effective amount of at least one compound of Formula (I) according to any one of claims 1 to 14, or a pharmaceutical composition according to claim 15, wherein the disease or disorder is selected from the group consisting of liver cancer, oral cancer, ovarian cancer, bladder cancer, lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, and gastric cancer.

17. A method of inhibiting the proliferation of a cell, comprising exposing a cell with an effective amount of at least one compound of Formula (I) according to any one of claims 1 to 14, or a pharmaceutical composition according to claim 15, wherein the cell is selected from the group consisting of HepG2, OML-1, MOC2, A2780, Kuramochi, UMUC3, J82, BFTC 905, A549, H460, MCF-7, MDA-MB231, PC3, 22RV1, BxPC3, SW1990, HT-29, DLD-1, AGS, and MKN45.

18. Use of at least one compound of Formula (I) according to any one of claims 1 to 14, or a pharmaceutical composition according to claim 15, for treating a disease or disorder selected from the group consisting of liver cancer, oral cancer, ovarian cancer, bladder cancer, lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, and gastric cancer.

19. Use of at least one compound of Formula (I) according to any one of claims 1 to 14, or a pharmaceutical composition according to claim 15, for inhibiting the proliferation of a cell selected from the group consisting of HepG2, OML-1, MOC2, A2780, Kuramochi, UMUC3, J82, BFTC 905, A549, H460, MCF-7, MDA-MB231, PC3, 22RV1, BxPC3, SW1990, HT-29, DLD-1, AGS, and MKN45.

20. Use of at least one compound of Formula (I) according to any one of claims 1 to 14, or a pharmaceutical composition according to Claim 15, for the manufacture of a medicament for treating a disorder, comprising administering to a subject a therapeutically effective amount of a compound of Formula (I) according to any one of claims 1 to 14 or a pharmaceutically acceptable salt, solvate, or isomer thereof, or a pharmaceutical composition according to claim 15, wherein the disease or disorder is selected from the group consisting of liver cancer, oral cancer, ovarian cancer, bladder cancer, lung cancer, breast cancer, prostate cancer, pancreatic cancer, colorectal cancer, and gastric cancer.

Images